US Pat. No. 10,188,654

USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER

Asana BioSciences, LLC, ...

1. A method of treating a cancer subject, comprising administering to a cancer subject in need thereof, a therapeutically effective amount of a compound 2-(1-(4-((4-(4-hydroxypiperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile, or a pharmaceutically acceptable salt or ester thereof, wherein:the cancer subject has a recurrent or refractory cancer;
the cancer is a hematopoietic cancer; and
the cancer is refractory to Ibrutinib.
US Pat. No. 10,189,936

BLOCK COPOLYMER, DISPERSANT, AND PIGMENT DISPERSION COMPOSITION

OTSUKA CHEMICAL CO., LTD....

1. A block copolymer of an ABA type including an A block and a B block and having an acid value of 30 to 250 mgKOH/g, the B block containing a structural unit derived from a vinyl monomer with an acid group, wherein a structural unit derived from a vinyl monomer with an acid group and contained in the A block is at a content of 10% by mass or less in 100% by mass of the A block.
US Pat. No. 10,189,937

FINE POWDER-COATED AMINE AND COMPOSITION CONTAINING SAME

SUNSTAR ENGINEERING INC.,...

1. A fine powder-coated amine comprising a solid amine having a melting point equal to or higher than 50° C. and a mean particle size equal to or smaller than 20 ?m, wherein the fine powder-coated amine has an amount of heat in the second absorption peak measured by a differential scanning calorimeter equal to or less than 220 J/g, and the surface of the solid amine is coated with fine particles having a mean particle size equal to or smaller than 2 ?m.
US Pat. No. 10,190,194

COPPER ALLOY FOR ELECTRONIC AND ELECTRICAL EQUIPMENT, COPPER ALLOY THIN SHEET FOR ELECTRONIC AND ELECTRICAL EQUIPMENT, AND CONDUCTIVE COMPONENT FOR ELECTRONIC AND ELECTRICAL EQUIPMENT, TERMINAL

MITSUBISHI MATERIALS CORP...

1. A copper alloy for electronic and electrical equipment, comprising:more than 2.0 mass % to 36.5 mass % of Zn;
0.10 mass % to 0.90 mass % of Sn;
0.15 mass % to less than 1.00 mass % of Ni;
0.005 mass % to 0.100 mass % of P; and
a balance containing Cu and inevitable impurities,
wherein an atomic ratio Ni/P of an amount of Ni to an amount of P satisfies a relationship of 3.00 an atomic ratio Sn/Ni of an amount of Sn to an amount of Ni satisfies a relationship of 0.10 a strength ratio TSTD/TSLD is 1.10 or more, where strength TSTD is obtained when a tensile test is performed in a direction perpendicular to a rolling direction and strength TSLD is obtained when another tensile test is performed in a direction parallel to the rolling direction.
US Pat. No. 10,188,657

COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND THERAPY FOR MENIERE'S DISEASE

1. A method comprising administering to an individual diagnosed with Meniere's Disease a pharmaceutical composition comprising an effective amount of lamotrigine or a pharmaceutically acceptable salt thereof such that the effective amount of the lamotrigine or the pharmaceutically acceptable salt thereof is sufficient to reduce dizziness that is caused by the Meniere's Disease in the individual, and wherein the lamotrigine or the pharmaceutically acceptable salt thereof is the only bioactive compound in the pharmaceutical composition that is effective to treat the dizziness caused by the Meniere's Disease.
US Pat. No. 10,189,941

POLYCARBONATE COMPOSITIONS CONTAINING POLYETHYLENE WAX

Covestro Deutschland AG, ...

1. A polycarbonate composition comprisingA) polycarbonate
B) oxidized acid-modified polyethylene wax and
D) an inorganic filler,
wherein the oxidized acid-modified polyethylene wax has an acid number of <10 mg KOH/g determined according to JIS K0070, a crystallinity of greater than 60% and less than 90%, a melting point between 90° C. and 130° C. and a viscosity average molar mass determined by viscometry between 1500 g/mol and 5000 g/mol.
US Pat. No. 10,188,660

ANTI-HULRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE

AbbVie Inc., North Chica...

1. An anti-huLRRC15 antibody drug conjugate (ADC) comprising an antimitotic agent linked to an anti-huLRRC15 antibody by way of a linker, wherein the ADC has a structure of formula (I):[D-L-XY]n-Ab  (I)
or a salt thereof, wherein:
D is the antimitotic agent;
L is the linker;
Ab is the anti-huLRRC15 antibody;
XY represents a covalent linkage linking linker L to antibody Ab; and
n is an integer ranging from 2 to 8;
wherein
Ab comprises
a VH chain comprising the sequence of SEQ ID NO:16 and a VL chain comprising the sequence of SEQ ID NO:17,
a VH chain comprising the sequence of SEQ ID NO:26 and a VL chain comprising the sequence of SEQ ID NO:27,
a VH chain comprising the sequence of SEQ ID NO:36 and a VL chain comprising the sequence of SEQ ID NO:37,
a VH chain comprising the sequence of SEQ ID NO:46 and a VL chain comprising the sequence of SEQ ID NO:47,
a VH chain comprising the sequence of SEQ ID NO:56 and a VL chain comprising the sequence of SEQ ID NO:57,
a VH chain comprising the sequence of SEQ ID NO:66 and a VL chain comprising the sequence of SEQ ID NO:67, or
a VH chain comprising the sequence of SEQ ID NO:76 and a VL chain comprising the sequence of SEQ ID NO:77.
US Pat. No. 10,190,198

THICK FILM PASTE AND USE THEREOF

E I DU PONT DE NEMOURS AN...

1. A thick film paste composition comprising:(a) inorganic constituents that consist of:
a platinum source that is at least one of a particulate platinum (alloy) or a particulate platinum (alloy)/metal oxide composite, and
at least one metal compound selected from the group consisting of particulate metal oxides and precursor compounds capable of forming a metal oxide on firing, the metal oxide in each case being selected from the group consisting of NiO, SiO2, RuO2, Rh2O3, IrO2, Cu2O, CuO, TiO2, ZrO2, PbO, SnO2, CeO2, Al2O3, MgO, and MnO2; and
(b) an organic vehicle,
and wherein:
the proportion of the at least one metal compound is 0.001 to 1 wt. %, based on the total thick film paste composition; and
the thick film paste composition is capable of being fired to form an electrically conductive metallization that is electrically connected with an electrode on a ceramic sensor substrate.
US Pat. No. 10,189,943

COPOLYMERS SUITABLE FOR MAKING MEMBRANES

BASF SE, Ludwigshafen (D...

1. A copolymer, comprising polyarylene ether blocks and hydrophilic-hydrophobic blocks,wherein:
said hydrophilic-hydrophobic blocks comprise polyisobutene blocks; and
said hydrophilic-hydrophobic blocks comprise polyisobutene blocks with terminal phenolic ether groups, and said phenolic ether groups are etherified with polyalkyleneoxides.
US Pat. No. 10,189,945

METHOD FOR PRODUCING LIGHT-COLOURED TDI-POLYISOCYANATES

Covestro Deutschland AG, ...

1. A method for producing polyisocyanates comprising urethane groups and having APHA colour indices <50 Hazen comprising reacting di- to tetra-valent organic polyhydroxy compounds with excess amounts of toluylene diisocyanate and then removing unreacted excess toluylene diisocyanate to residual contents <0.5 wt. % by distillation, wherein the toluylene diisocyanate has a content of 2-chloro-6-isocyanato-methylcyclohexadienes <5 wt·ppm.
US Pat. No. 10,188,667

PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11?-17-21-TRIOL-3,20-DIONE DERIVATIVES

ALLERGAN, INC., Irvine, ...

1. A method of treating an ocular condition associated with glucocorticoid and or mineralocorticoid receptor modulation which comprises topically administering to a patient in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of at least one compound selected from:(8S,9S,10R,11S,13S,14S,17R)-17-glycoloyl-11-hydroxy-10,13 -dimethyl-3 -oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl phenylacetate;
(8S,9S,10R,11S,13S,14S,17R)-17-glycoloyl-11-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl butyrate;
(8S,9S,10R,11S,13S,14S,17R)-17-glycoloyl-11-hydroxy-10,13 -dimethyl-3 -oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl propionate;
(8S,9S,10R,11S,13S,14S,17R)-17-glycoloyl-11-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl octanoate;
(8S,9S,10R,11S,13S,14S,17R)-17-Glycoloyl-11-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl hexanoate;
(8S,9S,10R,11S,13S,14S,17R)-17-glycoloyl-11-hydroxy-10,13 -dimethyl-3 -oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl benzoate;
(8S,9S,10R,11S,13S,14S,17R)-17-glycoloyl-11-hydroxy-10,13 -dimethyl-3 -oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl heptanoate;
(8S,9S,10R,11S,13S,14S,17R)-17-glycoloyl-11-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl 2-methylpropanoate; and
(8S,9S,10R,11S,13S,14S,17R)-17-glycoloyl-11-hydroxy-10,13 -dimethyl-3 -oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl cyclopentanecarboxylate,
and further comprising carboxymethylcellulose, sodium phosphate, citrate buffer, and sodium chloride,
and having a pH from about 4.5 to 7.5.
US Pat. No. 10,189,952

DEGRADABLE THIOL-ENE POLYMERS

REGENTS OF THE UNIVERSITY...

21. A method for producing a biocompatible thiol-ene hydrogel, the method comprisingsubjecting a polymerization reaction mixture comprising at least one thiol compound and at least one olefin compound to a radical polymerization reaction under conditions sufficient to produce the biocompatible thiol-ene hydrogel, wherein:
(a) the at least one thiol compound comprises m number of reactive thiol groups;
(b) the at least one olefin compound comprises n number of reactive ene groups; and
(c) each of n and m is an integer of at least 2, provided the sum of n+m is at least 5.
US Pat. No. 10,190,219

ELECTRICAL STEEL SHEET

1. An electrical steel sheet, comprising:a base material of electrical steel; and
an insulating film formed on a surface of the base material,
wherein the insulating film contains a phosphate of one or more selected from the group consisting of Al, Zn, Mg and Ca,
wherein a proportion of an amount by mole (mol) of Fe atoms relative to an amount by mole (mol) of P atoms in the insulating film is not less than 0.30 and not more than 0.65, and
a limit sodium chloride concentration is 0.1 mass % or more,
wherein the limit sodium chloride concentration represents a maximum concentration of the sodium chloride solution with which the electrical steel sheet does not rust when 0.5 ?L liquid droplets of sodium chloride solutions different in concentration are deposited on the surface of the electrical steel sheet having the insulating film and dried, and the electrical steel sheet is held in an atmosphere with constant temperature and humidity of a temperature of 50° C. and a relative humidity of 90% for 48 hours.
US Pat. No. 10,190,226

REACTION PRODUCTS OF HETEROCYCLIC NITROGEN COMPOUNDS POLYEPOXIDES AND POLYHALOGENS

Rohm and Haas Electronic ...

1. A compound comprising a reaction product of one or more heterocyclic nitrogen compounds comprising at least two reactive nitrogen atoms with the proviso that at least one of the reactive nitrogen atoms is in the ring of the one or more heterocyclic nitrogen compounds; one or more polyepoxide compounds and one or more polyhalogen compounds, wherein the one or more polyhalogen compounds have a formula:X1—R13—X2  (VII)wherein X1 and X2 may be the same or different and are halogens chosen from chlorine, bromine, fluorine and iodine, R13 is linear or branched, substituted or unsubstituted (C1-C20)alkyl, or is a moiety having formula:—C(HR14)—R15—C(HR14)—  (VIII)wherein each R14 is independently selected from hydrogen, halogens chosen from chlorine, bromine, fluorine and iodine, linear or branched, substituted or unsubstituted (C1-C18)alkyl, substituted or unsubstituted (C6-C12)cycloalkyl, substituted or unsubstituted (C6-C15)aryl; R15 is linear or branched, substituted or unsubstituted (C1-C18)alkyl, substituted or unsubstituted (C6-C12)cycloalkyl, substituted or unsubstituted (C6-C15)aryl, —CH2—O—(R16—O)d—CH2— where R16 is a substituted or unsubstituted, linear or branched (C2-C10)alkyl and d is an integer of 1-10.
US Pat. No. 10,189,716

ZEOLITE MONOLITH AND METHOD OF MAKING THE SAME, COMPOSITE WITH ZEOLITE MONOLITH AND METHOD OF MAKING THE SAME, AND METHOD FOR INCORPORATING TWO OR MORE ZEOLITE MONOLITHS

1. A method of manufacturing a porous monolithic zeolite structure including the steps of:(a) taking a porous monolithic substrate;
(b) forming one or more zeolites on the substrate; and
(c) substantially or completely removing said substrate.
US Pat. No. 10,189,976

CURABLE COMPOSITION COMPRISING AN ETHYLENE POLYMER, A MONOPEROXYCARBONATE AND A T-ALKYL HYDROPEROXIDE

ARKEMA FRANCE, Colombes ...

1. A curable composition comprising:(a) at least one ethylene polymer,
(b) at least one monoperoxycarbonate, and
(c) from 0.05 to less than 0.4 part by weight of at least one t-alkyl hydroperoxide for 100 parts by weight of constituent (b).
US Pat. No. 10,189,979

NUCLEATED PHTHALATE-FREE PP HOMOPOLYMERS FOR MELT-BLOWN FIBERS

BOREALIS AG, Vienna (AT)...

1. A polypropylene composition suitable for the production of meltblown PP fibers comprising:(A) a propylene homopolymer, produced with a Ziegler-Natta catalyst (ZN-C), and
(B) a polymeric nucleating agent,
wherein the polypropylene composition has
i) a melt flow rate MFR2 (230° C./2.16 kg) measured according to ISO 1133 of 90 to 5000 g/10 min, and
ii) a difference between melting temperature (Tm) and crystallization temperature (Tc), (Tm?Tc) of <45° C., and
wherein the propylene homopolymer has been visbroken and has an MFR2 of 400 to 3000 g/10 min.
US Pat. No. 10,188,698

SAPOSIN C-DOPS: A NOVEL ANTI-TUMOR AGENT

1. A method for decreasing tumor volume in a subject comprising the step of administering to the subject a composition comprisinga phospholipid, wherein the phospholipid is phosphatidylserine;
an isolated saposin C-related polypeptide, wherein the polypeptide has an amino acid sequence at least 85 percent identical to SEQ ID NO: 2 and wherein the polypeptide includes amino acids 24-40 of SEQ ID NO:2; and
wherein the phospholipid forms a nanovesicle incorporating the polypeptide.
US Pat. No. 10,188,702

METHODS AND COMPOSITIONS FOR TREATING HYPOGLYCEMIC DISORDERS

THE TRUSTEES OF THE UNIVE...

1. A method of treating congenital hyperinsulinism in a subject having congenital hyperinsulinism comprising administering to the subject an effective amount of a peptide wherein the amino acid sequence of the peptide consists of the amino acid sequence set forth in SEQ ID NO: 1.
US Pat. No. 10,188,704

ENHANCED MELANOMA CANCER PREVENTION BY NOVEL MELANOTROPINS

ARIZONA BOARD OF REGENTS ...

wherein Waa is a Met, Ile, or Leu, Xaa is a His or Pro, Yaa is an Arg or Leu, and Zaa is a Phe or Trp, and wherein R1 of the C-terminal is —NH2, or —OH, with the caveat that Waa is not Met, Xaa is not His, Yaa is not Arg, Zaa is not Trp, and R1 is not OH simultaneously.
US Pat. No. 10,189,217

METHOD FOR PREPARING THERMOPLASTIC PREPREG AND THERMOPLASTIC PREPREG PREPARED THEREBY

KOLON INDUSTRIES, INC., ...

1. A method for preparing a thermoplastic prepreg, comprising:laminating a thermoplastic resin film having a crystallization degree in a range of 1 to 20% on at least one surface of a matrix fiber to give a laminate; and
heating the laminate to a higher temperature than a melting point of the thermoplastic resin film, then, pressing the heated laminate,
wherein the thermoplastic prepreg has a weight variation per unit area of 3-5%,
said weight variation per unit area being determined by the following equation (I) or (II):
weight variation per unit area (%)=[(W0?W1)/W0]×100  (I)
weight variation per unit area (%)=[(W1?W0)/W0]×100  (II)
wherein W0 is an average weight of 10 samples of the thermoplastic prepreg, and
W1 is a weight of the samples which show the greatest difference from the average weight W0.
US Pat. No. 10,188,707

ENOLASE 1 (ENO1) COMPOSITIONS AND USES THEREOF

Berg, LLC, Framingham, M...

1. A pharmaceutical composition comprising enolase 1 (Eno1) or a fragment thereof and a muscle targeting peptide, wherein the Eno1 or a fragment thereof and the muscle targeting peptide are in a complex;wherein the Eno1 or a fragment thereof has glycolytic activity and is present in a therapeutically effective amount; and
wherein the muscle targeting peptide is a smooth muscle targeting peptide, a skeletal muscle targeting peptide, or a smooth muscle and skeletal muscle targeting peptide.
US Pat. No. 10,189,993

SILOXANE COMPOSITION AND METHOD FOR PRODUCING SAME

SHIN-ETSU CHEMICAL CO., L...

1. A method of preparing a siloxane composition, comprising:a step of producing a crosslinked organopolysiloxane having a weight-average molecular weight of 5,000 to 300,000,000 and containing 0.1 to 50 moles of silethylene linkages per 1,000 moles of siloxane units by hydrosilylation of an organopolysiloxane having a structure of formula (1) below with an organohydrogenpolysiloxane having a structure of formula (2) below
M?MVi?D?DVi?T?TVi?Q?  (1)
M?MH?D?DH?T?TH?  (2)(wherein M is R3SiO1/2, MVi is R2PSiO1/2, D is R2SiO2/2, DVi is RPSiO2/2, T is RSiO3/2, TVi is PSiO3/2, MH is R2HSiO1/2, DH is RHSiO2/2, TH is HSiO3/2 and Q is SiO4/2, each R being independently an unsubstituted or substituted monovalent hydrocarbon group of 1 to 12 carbon atoms that has no aliphatic unsaturated bonds and P being an alkenyl group represented by —(CH2)a—CH?CH2 (where “a” is 0 or an integer from 1 to 6); and ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ?, ? and ? are each independently 0 or a positive number, with the provisos that ?, ? and ? are not all 0, ?+?+??2, ?, ? and ? are not all 0, and ?+?+??2) in an amount of solvent that is at least 8 times the combined weight of the polysiloxanes of formulas (1) and (2) and using a platinum group metal compound, andafter obtaining the crosslinked organopolysiloxane using an organic solvent selected from among toluene, hexane, xylene and methyl ethyl ketone as the solvent: adding a low-viscosity organopolysiloxane as a solvent, and distilling off the organic solvent by heating under reduced pressure so as to give a composition that contains no organic solvent.
US Pat. No. 10,190,002

AQUEOUS MULTI-STAGE EMULSION COPOLYMER COMPOSITIONS FOR USE IN JOINERY APPLICATIONS

Rohm and Haas Company, P...

1. An aqueous composition comprising aqueous multistage emulsion copolymer compositions comprising (a) one or more dihydrazide compounds in a total amount of from 0.5 to 4 wt. %, based on the total weight of composition solids, and (b) of one or more aqueous multistage emulsion copolymers containing, as (i) a first stage, an emulsion copolymer having a glass transition temperature (Tg) via differential scanning calorimetry (DSC) of from ?50 to 30° C., and containing, in copolymerized form, from 0.5 to 3.0 wt. % of one or more monoethylenically unsaturated phosphorous acid monomers and, from 0.75 to 5 wt. % of one or more keto group containing amide monomers, and, as (ii) a second stage, an emulsion copolymer having a DSC Tg of from 50° C. to 125° C., wherein the Tg difference between the first stage and the second stage is from 45° C. to 150° C. having a weight ratio of (i) the first stage to (ii) the second stage, based on copolymer solids, ranging from 50:50 to 90:10 or, all monomer wt. % s based on the total weight of monomers used to make the aqueous multistage emulsion copolymer, and, further wherein, the (ii) second stage of the aqueous multistage emulsion copolymer comprises, in copolymerized form, no more than 25 wt. % of the total monoethylenically unsaturated phosphorous acid monomers used to make the aqueous multistage emulsion copolymer, and no more than 50 wt. % of the total keto group containing amide monomers used to make the aqueous multistage emulsion copolymer, and wherein (b) at least one of the one or more aqueous multistage emulsion copolymer comprises, in copolymerized form, at least 90 wt. % of the one or more monoethylenically unsaturated phosphorous acid monomers in the (i) first stage.
US Pat. No. 10,188,723

FUNCTIONAL INFLUENZA VIRUS LIKE PARTICLES (VLPS)

NOVAVAX, INC., Gaithersb...

1. A vaccine comprising an influenza VLP, wherein said VLP comprises influenza proteins, wherein the influenza proteins consist of M1, HA and NA proteins; wherein the M1 protein is derived from a different influenza virus strain than the HA and NA proteins; wherein the influenza proteins are insect-cell expressed, and wherein the M1 protein is from an avian influenza strain.
US Pat. No. 10,190,261

STRENGTHENING RESINS FOR PAPER PRODUCTS

ECOLAB USA INC., St. Pau...

1. A fiber mixture, comprising:a plurality of fibers; and
a resin composition comprising:
about 10 wt % to about 80 wt % of a polyamide-epihalohydrin resin comprising a reaction product of a polyamidoamine and an epihalohydrin;
about 10 wt % to about 80 wt % of a cationic styrene maleimide resin comprising a reaction product of a styrene maleic anhydride copolymer and an amine compound; and
about 10 wt % to about 80 wt % of a urea-formaldehyde resin, wherein the weight percent values of the polyamide-epihalohydrin resin, the cationic styrene maleimide resin, and the urea-formaldehyde resin are based on a combined solids weight of the polyamide-epihalohydrin resin, the cationic styrene maleimide resin, and the urea-formaldehyde resin.
US Pat. No. 10,188,726

SYNTHETIC HEPATITIS C POLYPEPTIDE AND METHODS OF MAKING AND USING SAME

The Johns Hopkins Univers...

1. The polypeptide encoded by a nucleic acid comprising SEQ ID NO: 1, encoding the genome of the synthetic hepatitis C virus subtype 1a (Bole 1a).
US Pat. No. 10,188,984

PROCESS FOR REMOVING OXIDISABLE GASEOUS COMPOUNDS FROM A GAS MIXTURE BY MEANS OF A PLATINUM-CONTAINING OXIDATION CATALYST

1. A process for catalytic oxidative removal of at least one oxidisable gaseous compound from a gas mixture, the gas mixture comprising the at least one oxidisable gaseous compound as well as oxygen, the process comprising:reacting H2Pt(OH)6 with oxalic acid in an aqueous solution to form platinum oxalate complexes of the formula (H3O)1.6[Pt(C2O4)2]. 2H2O;
forming an oxidation catalyst by adding the platinum oxalate complexes to a porous catalyst support and exothermically decomposing the platinum oxalate complexes to generate catalytically active platinum species; and
oxidizing the gas mixture with the oxidation catalyst, wherein
the gas mixture is not a combustion flue gas.
US Pat. No. 10,188,729

MODULATION OF TUMOR IMMUNITY

1. A method of treating a tumor in a patient comprising administering to the patient a bispecific antibody comprising(i) a first arm having a light chain (LC) variable region that comprises the amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 of an LC variable region having the amino acid sequence of the LC variable region of MK-3475 and a heavy chain (HC) variable region that comprises the amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 of an HC variable region having the amino acid sequence of the HC variable region of MK-3475; and
(ii) a second arm having an LC variable region that comprises the amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 of an LC variable region having the amino acid sequence set forth in SEQ ID NO: 82 wherein residue 31 is Q and residue 57 is Q; and an HC variable region that comprises the amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 of an HC variable region having the amino acid sequence set forth in SEQ ID NO: 81.
US Pat. No. 10,193,094

ORGANIC LIGHT-EMITTING DEVICE HAVING DELAYED FLUORESCENCE

Merck Patent GmbH, (DE)

1. An organic electroluminescent device comprisinganode,
cathode,
at least one emitting layer which comprises a luminescent organic compound E which has a difference between the energies of its S1 and T1 states of not greater than 0.15 eV, and
2, 3, 4 or 5 layers H each having a thickness of greater than 2 nm which are arranged between one emitting layer of said at least one emitting layer, which is closest to said anode, and said anode,
where the following conditions apply to each layer H:
a difference D between the HOMO energy level of a layer H and the HOMO energy level of the closest layer having a thickness of greater than 2 nm on a cathode side of this layer H must be less than or equal to 0.4 eV, and
each of the layers H comprises at least one triarylamino compound which is a small organic molecule,
with the proviso that, for layers whose HOMO energy level has a value of less than ?6.7 eV, the LUMO energy level for the said condition occurs instead of the HOMO energy level and wherein the emitting layer which comprises compound E additionally comprises one or more matrix materials, and in that compound E is an emitting compound and the energy of the T1 state of the matrix material of the emitting layer is at most 0.1 eV lower than the energy of the T1 state of compound E.
US Pat. No. 10,190,020

SILOXANE-BASED COATINGS CONTAINING POLYMERS WITH UREA LINKAGES AND TERMINAL ALKOXYSILANES

The United States of Amer...

8. A composition comprising:an amine-functional compound or an epoxy- or acrylate-functional compound; and
a urea-containing composition made by a method comprising:
reacting an amino-functional alkoxysilane with a first polyisocyanate to form one or more adducts having an unreacted isocyanate group; and
reacting the adducts with one or more polyfunctional amino- and/or hydroxyl compounds and a second polyisocyanate to form the urea-containing composition;
wherein the urea-containing composition comprises at least two residues of the polyfunctional amino- and/or hydroxyl compounds;
wherein isocyanate groups do not react with other isocyanate groups; and
wherein the urea-containing composition contains no unreacted isocyanate groups;
wherein the urea-containing composition is characterized by any of:
a) at least one of the polyfunctional amino- and/or hydroxyl compounds comprises an amino group and at least one of the polyfunctional amino- and/or hydroxyl compounds comprises a hydroxyl group;
b) at least one of the polyfunctional amino- and/or hydroxyl compounds is a polyfunctional amino compound; and
c) the urea-containing composition comprises one of more compounds having the formula:
{[(R1O)aR13-aSi—(CH2)3—NR2—CO—NH]n—R3—NH—CO—X—R5—X—CO—NH}m—R3
wherein each a is independently selected from 1, 2, or 3;
wherein m is 2 or 3;
wherein each n is independently selected from 1 or 2;
wherein each X is independently selected from —NR4— and —O—;
wherein each R1 group is an independently selected alkyl group;
wherein each R2 and R4 is independently selected from hydrogen, aryl, alkyl, cycloalkyl, ester-containing aliphatic, ester-containing fluorinated aliphatic, amide-containing aliphatic, and polysiloxane;
wherein each R3 is an independently selected residue of an aliphatic, cycloaliphatic, or aromatic polyisocyanate having 2 or 3 isocyanate groups; and
wherein each R5 independently comprises a group selected from aliphatic, cycloaliphatic, aromatic, polyester, polyether, polysulfide, polyurethane, polycarbonate, polysiloxane, and any combination thereof moisture-curing the composition.
US Pat. No. 10,193,097

LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, AND ELECTRONIC DEVICE

Semiconductor Energy Labo...

10. A light-emitting element comprising:a first electrode;
a hole-injecting layer over the first electrode
a hole-transporting layer over the hole-injecting layer;
a light-emitting layer over the hole-transporting layer;
an electron-transporting layer over the light-emitting layer;
an electron-injecting layer over the electron-transporting layer;
a second electrode over the electron-injecting layer;
a first layer between the hole-transporting layer and the light-emitting layer; and
a second layer between the light-emitting layer and the electron-transporting layer,
wherein:
the light-emitting layer includes a first phosphorescent compound,
the first layer includes a first hole-transporting material and a first electron-transporting material,
the second layer includes a second hole-transporting material and a second electron-transporting material,
the second hole-transporting material includes a second phosphorescent compound,
in the first layer, a concentration of the first hole-transporting material is higher than that of the first electron-transporting material,
in the second layer, a concentration of the second electron-transporting material is higher than that of the second hole-transporting material, and
a difference between a wavelength of a highest peak of an emission spectrum of the second phosphorescent compound and a wavelength of a highest peak of an emission spectrum of the first phosphorescent compound is within 30 nm.
US Pat. No. 10,189,764

HYDROGENATION OF OXYGENATED MOLECULES FROM BIOMASS REFINING

VIRDIA, INC., Raceland, ...

1. A method for producing 2-butanone and a conversion product, the method comprising:dehydrogenating 2-butanol to yield 2-butanone, thereby releasing hydrogen;
using hydrogen released from the dehydrogenating in a conversion reaction, wherein the conversion reaction converts a biomass-derived molecule to a conversion product; and
recovering 2-butanone and the conversion product.
US Pat. No. 10,188,740

MODIFIED FC MOLECULES

AMGEN INC., Thousand Oak...

1. A composition of matter comprising:(i) a monomeric or multimeric Fc domain having a cysteine or non-canonical amino acid substitution at one or more specifically selected conjugation site(s) selected from D46, S48, H49, E50, E53, K55, D61, G62, Q76, Y81, K107, K121, G122, Q123, E126, R136, D137, T140, K141, N142, E169, N170, N171, K173, L179, S181, G183, D194, K195, R197, Q199, Q200, G201, N202, or S223, relative to reference sequence SEQ ID NO:599; and
(ii) at least one additional functional moiety, wherein the functional moiety is conjugated to the Fc domain through the side chain of the cysteine residue or non-canonical amino acid residue substituted at said one or more conjugation site(s).
US Pat. No. 10,189,766

PROCESS FOR PRODUCING 2-ETHYLHEXANAL HELPING TO IMPROVE YIELD

NAN YA PLASTICS CORPORATI...

1. A process for producing 2-ethylhexanal helping to increase yield of 2-ethylhexanal, comprises the following steps:1) placing a reaction liquid containing 60-100 wt % of 2-ethyl-2-hexenal into a single reaction tank having internally equipped with a gas-introducing mixer which comprising a hollow rotatory shaft thereof and vanes at a terminal of the hollow rotatory shaft for use in introducing and exhausting hydrogen gas to the reaction liquid and simultaneously stirring the reaction liquid if started;
2) based on the weight of 2-ethyl-2-hexenal, adding a palladium on carbon catalyst ranged from 0.02 wt % to 15 wt % for hydrogenation, whose palladium component is supported on a carbon carrier having a total content of impurities less than 8% by weight of the carbon carrier, and whose specific surface area of the impurities of the carbon carrier is ranged between 800 m2/g and 3,000 m2/g;
3) introducing hydrogen gas to 80-600 lb/in2 and holding this pressure;
4) activating the gas-introducing mixer to stir the reaction liquid at room temperature and held the pressure for 10 minutes, heating to 70-150° C., and allowing hydrogenation for 1-10 hours at this temperature; and
5) upon completion of the reaction, cooling the reaction liquid to room temperature and filtering out the catalyst to obtain a yield of the 2-ethylhexanal at least up to 98.0%.
US Pat. No. 10,191,303

MULTIFOCAL BIMODULUS CONTACT LENSES

NexisVision, Inc., Menlo...

1. An ophthalmic lens for correcting presbyopia of an eye, the eye having a cornea characterized by a refractive shape extending across an optical region of the cornea, the ophthalmic lens comprising:an inner optic portion and a peripheral portion disposed radially outward of the inner optic portion, wherein,
the inner optic portion is configured to be disposed over the optical region of the cornea;
the inner optic portion is characterized by an inner rigidity and the peripheral portion is characterized by a peripheral rigidity;
the inner rigidity is greater than the peripheral rigidity; and
the inner rigidity is from about 1E8 MPa-?m3 to about 1E11 MPa-?m3; and
an anterior surface and a posterior surface opposite the anterior surface, wherein,
a portion of the anterior surface is configured to correct presbyopia; and
the posterior surface is configured to provide one or more lenticular volumes between the posterior surface and the optical region of the cornea.
US Pat. No. 10,188,742

BI-SPECIFIC ANTIBODIES AND USES THEREOF

KAOHSIUNG MEDICAL UNIVERS...

1. A humanized bi-specific antibody against the terminal methoxy or hydroxyl group of polyethylene glycol (PEG) and a target ligand, comprising,a first antigen binding site that binds to the PEG; and
a second antigen binding site that binds to the target ligand that is HER2;
wherein,
the first antigen binding site comprises the first VL-Ck domain consisting of SEQ ID NO: 12, the first VH-CH1 domain consisting of SEQ ID NO: 13, and the first HR-CH2-CH3 domain consisting of SEQ ID NO: 22; and
the second antigen binding site comprises a humanized single chain variable fragment (scFv) consisting of SEQ ID NO: 15.
US Pat. No. 10,189,767

PROCESS FOR MANUFACTURING SUCCINIC ACID FROM A FERMENTATION BROTH USING NANO FILTRATION TO PURIFY RECYCLED MOTHER LIQUOR

DSM IP ASSETS B.V., Heer...

1. A process for manufacturing succinic acid comprising:a) providing an aqueous solution of succinic acid;
b) crystallizing the succinic acid from the aqueous solution to form intermediate crystals and a mother liquor;
c) separating the intermediate crystals from the mother liquor;
d) treating the mother liquor by nanofiltration;
e) recycling the treated mother liquor to b);
f) purifying the intermediate crystals; and
g) recovering succinic acid.
US Pat. No. 10,191,048

FLUOROMETRIC IMMUNOASSAY FOR DETECTION OF ANTI-DSDNA ANTIBODIES

1. A fluorometric immunoassay method for detecting antibodies against double-stranded DNA (anti-dsDNA), comprisingproviding decomplemented sera from a patient, providing isolated dsDNA as antigens from a source,
Precipitating immune complexes with a saturated solution of ammonium sulfate or solution of polyethylene glycol (PEG), wherein the immune complexes are a consequence of incubation of decomplemented patient's sera with the dsDNA,
separating the immune complexes into two samples,
labeling the samples by adding fluorescent dyes specific to the dsDNA to the samples, and
detecting of fluorescence in the samples, namely sample with supernatant and sample with precipitate, comprising immune complexes comprising dsDNA and anti-dsDNA,
wherein the detected fluorescence is a consequence of binding of fluorescent dyes into the dsDNA.
US Pat. No. 10,188,744

AMPHIPATHIC PEPTIDE

1. An amphipathic cell penetrating peptide of less than 50 amino acid residues comprising at least 6 arginine residues (R), at least 12 alanine residues (A), at least 6 leucine residues (L), optionally at least one cysteine residue (C) and at least two but no greater than three glutamic acids (E) whereinthe arginine (R) residues are evenly distributed along the length of the peptide;
the ratio of arginine (R) to negatively charged glutamic acid (E) residues is from at least 6:2 to 9:2; and
the ratio of hydrophilic amino acid residues to hydrophobic amino acid residues at pH 7 is at least 30:67 to 40:60; or
wherein the peptide comprises or consists of WEARLARALARALARELARALARALRACEA (SEQ ID No. 4).
US Pat. No. 10,190,026

WOOD ADHESIVE

INDUSTRIAL TECHNOLOGY RES...

1. A wood adhesive, consisting of:a first agent, consisting of:
a sodium carboxymethyl cellulose having a molecular weight between 15,000 and 500,000 and a degree of substitution of from 0.4 and 2.00 of the sodium salt; and
a styrene-butadiene rubber polymer; and
a second agent, consisting of:
a polymeric quaternary amine and NaOH, wherein a ratio of the weight of the styrene-butadiene rubber polymer to the sum of weights of the sodium carboxymethyl cellulose and the polymeric quaternary amine is in the range from 0.05:1 to 1:0.1.
US Pat. No. 10,190,027

HOT MELT ADHESIVE

1. A hot melt adhesive comprising:(A) 1-15 wt % of a polar functional group-modified conjugated diene-based polymer;
(B) 10-50 wt % of a butyral resin;
(C) 5-40 wt % of an olefin-based polymer;
(D) 5-70 wt % of a tackifier resin; and
(E) 10-40 wt % of a wax.
US Pat. No. 10,188,747

METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER

The General Hospital Corp...

1. A method of treating squamous cell carcinoma in a subject in need of treatment thereof, the method comprising administering to the subject an agonist of a gene selected from the group consisting of:Esr2; Dlx5; and Egr3.
US Pat. No. 10,189,772

MIXTURES OF CHELATING AGENTS INCLUDING AN L-ENANTIOMER-RICH MGDA, AND PROCESS FOR MAKING SUCH MIXTURES

BASF SE, Ludwigshafen (D...

1. A mixture, comprising:(A) 90 to 99.9% by weight of a mixture of L- and D-enantiomers of methyl glycine diacetic acid (MGDA) or its respective mono-, di- or trialkali metal or mono-, di- or triammonium salts, said mixture containing predominantly the respective L-enantiomer with an enantiomeric excess (ee) in the range of from 10 to 99%, and
(B) in total 0.1 to 10% by weight of a diacetic acid derivative of at least one amino acid selected from the group consisting of valine, leucine, isoleucine, and tyrosine, as free acids or respective mono-, di- or trialkali metal or mono-, di- or triammonium salts,
wherein the percentages refer to the sum from (A) and (B).
US Pat. No. 10,190,029

REMOVABLE POLYURETHANE HOT MELT ADHESIVE AND THE USE THEREOF

1. A removable reactive hot melt adhesive comprising a (meth)acrylate polymer and an isocyanate-functional polyurethane prepolymer, wherein the (meth)acrylate polymer has a number average molecular weight from about 25000 g/mol to about 60000 g/mol and is selected from a copolymerization product of butyl acrylate and methyl methacrylate as monomers having a melting point of from about 100° C. to about 120° C., a copolymerization product of butyl methacrylate and methyl methacrylate as monomers having a melting point about 110° C., and combinations thereof; andwherein the cured adhesive has a bond strength of about 5.0 MPa or greater at room temperature and a bond strength of about 0.8 MPa or less at a temperature of about 70° C. to about 90° C.
US Pat. No. 10,188,748

PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED MRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS

1. A cell-free mRNA pharmaceutical composition comprising at least one modified mRNA and a pharmaceutically compatible carrier, wherein the modified mRNA encodes at least one human tumour-specific antigenic polypeptide capable of stimulating an immune response in a patient against the human tumour-specific antigenic polypeptide wherein said modified mRNA encoding the human tumour-specific antigenic polypeptide has been stabilized by increasing its Guanosine/Cytosine (G/C) content by at least 7 percentage points relative to that of the wild type mRNA encoding the tumour-specific antigenic polypeptide.
US Pat. No. 10,188,750

SELF-REPLICATING CELL SELECTIVE GENE DELIVERY COMPOSITIONS, METHODS, AND USES THEREOF

University of South Flori...

1. A polyribonucleotide comprising:a RNA molecule of interest (ROI), wherein the ROI is an RNA capable of being translated into p27;
a microRNA (miRNA) target sequence, wherein the miRNA target sequence is a target for miR-126, and wherein the miRNA target sequence is operatively linked to the ROI; and
a RNA molecule capable of being translated into a viral RNA replicase, wherein the RNA molecule capable of being translated into a viral RNA replicase is operatively linked to the ROI, the miRNA target sequence, or both the ROI and miRNA target sequence.
US Pat. No. 10,191,056

DIAGNOSTIC EVALUATION OF ANTIBODY RESPONSES TO COMMONLY RECOGNIZED PROSTATE CANCER-ASSOCIATED ANTIGENS

Wisconsin Alumni Research...

1. An antigen panel for identifying immunoreactivity associated with a premalignant or malignant prostate, the panel comprising antigens encoded by SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:40, SEQ ID NO:44, SEQ ID NO:64, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:86, and SEQ ID NO:91, the encoded antigens being immobilized on one of a membrane, a plate, and a filter, and having a positive likelihood ratio of at least 4.
US Pat. No. 10,189,008

ODOR AND COLOR STABLE WATER-ABSORBING COMPOSITION

Evonik Degussa GmbH, Ess...

1. A water-absorbing composition comprising at least: i) from 91.2 to 98.9 wt % of at least one water-absorbing polymer; ii) from 1 to 8 wt % of at least one oxidizing agent; and iii) from 0.1 to 0.75 wt % of at least one inhibitor to inhibit free-radical polymerizations; wherein the inhibitor is a hydroquinone or a hydroquinone derivative selected from the group consisting of hydroquinone, hydroquinone monomethyl ether (HQME), 1,4-dimethoxybenzene, 4,4?-oxydiphenol and a mixture of two or more thereof; and wherein the weight quantities are each based on the overall weight of the water-absorbing composition.
US Pat. No. 10,188,752

DUAL-MODALITY IMAGING PROBE FOR COMBINED LOCALIZATION AND APOPTOSIS DETECTION OF STEM CELLS

The Board of Trustees of ...

1. A dual-modality imaging probe for simultaneous, one-stop, cell apoptosis detection and stem cell tracking, comprising: ferumoxytol with a fluorescent signature peptide immobilized on the surface of the ferumoxytol, wherein the fluorescent signature peptide is a KKKKDEVD-AFC peptide (SEQ ID NO:1).
US Pat. No. 10,189,778

PROCESS FOR THE PREPARATION OF METHIONINE ALPHA-HYDROXY ANALOGUES FROM SUGARS AND DERIVATIVES THEREOF

1. A process for the preparation of a methionine ?-hydroxy analogue and derivatives thereof of the formula:R?—S—CH2—CH2—CHOH—COO—R  (I)wherein R is selected from the group consisting of H, C1-C8 alkyl, alkaline or alkaline-earth metals; and R? is selected from the group consisting of H and methyl; andwherein the process comprises a step of contacting one or more sugars or derivatives thereof selected from the group consisting of glucose, fructose, galactose, mannose, sucrose, xylose, erythrose, erythrulose, threose, glycolaldehyde, methyl vinyl glycolate,vinyl glycolic acid and 2-hydroxyl-?-butyrolactone with a metallo-silicate zeotype material, in the presence of a compound comprising sulphur and a solvent, wherein the metallo-silicate zeotype material has a framework structure selected from the group consisting of BEA, MFI, FAU, MOR, and FER, with a metal and/or metal oxide component.
US Pat. No. 10,189,779

METHODS FOR PRODUCING THIOL COMPOUNDS AND SULFIDE COMPOUNDS USING DIPHENYLAMINE OR A PHENOL COMPOUND

Chevron Phillips Chemical...

1. A process for producing a thiol compound, the process comprising:i) contacting:
a) an olefin compound;
b) H2S;
c) diphenylamine and/or a phenol compound comprising BHT, carvacrol, 2,2?-ethylidene-bis(4,6-di-tert-butylphenol), pentaerythritol tetrakis(3,5-di-tert-butyl-4-hydroxyhydrocinnamate), or any combination thereof; and
d) a photoinitiator and/or a free radical initiator; and
ii) forming the thiol compound.
US Pat. No. 10,188,757

CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT

The General Hospital Corp...

1. A method for treating Alzheimer's disease in a subject in need thereof comprising the steps of:a) administering to the subject by oral inhalation a dry powder formulation consisting essentially of 17.1 mg of micronized cromolyn sodium, 12.8 mg lactose monohydrate, and 0.6 mg micronized magnesium stearate; and
b) administering orally to the subject 1 mg, 2 mg, 5 mg, 10 mg, or 25 mg of a non-steroidal anti-inflammatory drug,
wherein Alzheimer's Disease is treated in the subject.
US Pat. No. 10,189,271

NON-FOAMING AQUEOUS PARTICLE-FREE INKJET INK COMPOSITIONS

EASTMAN KODAK COMPANY, R...

1. An aqueous colorless particle-free inkjet ink composition that has a viscosity of less than 5 centipoises (0.005 N-sec) at 25° C., and comprises:an anionic polyether polyurethane having an acid number of at least 50 and an anionic acrylic polymer or anionic styrene-acrylic polymer having an acid number of at least 50; wherein the weight ratio of the anionic polyether polyurethane to the anionic acrylic polymer or anionic styrene-acrylic polymer is from 1:9 to and including 9:1, and the total amount of the anionic polyether polyurethane and the anionic acrylic polymer or anionic styrene-acrylic polymer is less than or equal to 20 weight % based on the total aqueous colorless particle-free inkjet ink composition weight, and
a defoamer that has a hydrophilic-lipophilic balance value of at least 3 and up to and including 5, which defoamer is present in an amount of at least 0.15 weight % and up to and including 1 weight %, based on the total aqueous colorless particle-free inkjet ink composition weight.
US Pat. No. 10,188,760

MODULATION OF IMMUNITY AND CEACAM1 ACTIVITY

1. A method for diagnosing a cancer in a human patient, said method comprising the step of contacting a biological sample derived from said patient with a CEACAM1 binding agent conjugated to a detectable moiety, wherein the CEACAM1 binding agent comprises a multimer agent consisting of at least two peptides selected from the group consisting of GYSWYK (SEQ ID NO:33), NRQII (SEQ ID NO:34), and QNDTG (SEQ ID NO: 35).
US Pat. No. 10,190,045

NANO-COMPOSITE STRUCTURE AND PROCESSES MAKING OF

1. A nano-composite structure comprising a nano-composite material having an amorphous matrix with embedded nano-crystallites, wherein the amorphous matrix and the nano-crystallites are made of the same chemical elements, wherein the nano-composite structure exhibits no distinguishable crystalline grain boundaries between the amorphous matrix and the nano-crystallites, wherein the nano-composite structure comprises multiple layers of nano-composite material, the multiple layers of nano-composite material disposed one directly on top of another in direct contact, and wherein each of the nano-composite layers consists of the nano-composite material.
US Pat. No. 10,189,792

METHOD AND APPARATUS FOR SYNTHESIZING A WATER-SOLUBLE HEXAARYL BIIMIDAZOLE

1. A method for forming a water-soluble hexaaryl biimidazole, comprising the steps of:a) reacting benzil with a carboxy benzaldehyde and ammonium acetate to yield a carboxy triaryl imidazole; and
b) dimerizing said carboxy triaryl imidazole in an alkaline aqueous solution of potassium ferricyanide to yield a water-soluble salt of a bicarboxy hexaaryl biimidazole,
wherein said water-soluble salt of a bicarboxy hexaaryl biimidazole is the disodium salt of 2,2?-bicarboxy hexaaryl biimidazole.
US Pat. No. 10,193,132

SYNTHESIS OF SUBMICROMETER TO MICROMETER-SIZED CATHODE MATERIALS

Washington University, S...

1. A method of producing submicrometer- to micrometer-sized, spherical-shaped cathode materials for lithium ion batteries, the method comprising:dissolving a lithium salt and a metal salt in water, alcohol, oil or a mixture of any two or more thereof, forming a lithium metal precursor solution,
spraying the precursor solution to form fine aerosolized droplets,
flowing the aerosolized droplets in a carrier medium into a pyrolysis hydrogen flame producing submicrometer- to micrometer-sized spherical lithium-metal-oxide particles in a range of from about 0.1 ?m to about 100 ?m, wherein no external heat source is required, and wherein the droplets are flowing in an environment having a temperature of less than 1200° C., wherein the submicrometer- to micrometer-sized spherical-shaped lithium-metal-oxide particles produced have a formula of Li?M??O? wherein ? is 0???1; ? is 0???2; and ? is 0???4; and wherein M? is selected from the group consisting of Ni, Co, Mn, Al, Mg, Fe, Cu, Zn, V, Mo, Nb, Cr, Si, Ti, Zr, and a mixture of any two or more thereof.
US Pat. No. 10,188,774

METHOD FOR PRODUCING ANTITHROMBOTIC COATING MATERIAL

TERUMO KABUSHIKI KAISHA, ...

1. A method for producing an antithrombotic coating material, the method comprising:preparing a methanol solution containing a monomer consisting of methoxymethyl acrylate, methoxyethyl acrylate (MEA), ethoxymethyl acrylate, ethoxyethyl acrylate, methoxymethyl methacrylate, methoxyethyl methacrylate, ethoxymethyl methacrylate, ethoxyethyl methacrylate, or a combination thereof;
adding a radical polymerization initiator having a 10-hour half-life temperature of 60° C. or less to the methanol solution to prepare a polymerization reaction liquid, wherein the radical polymerization initiator having a 10-hour half-life temperature of 60° C. or less is 2,2?-azobis(4-methoxy-2,4-dimethylvaleronitrile); and
polymerizing the monomer to form a polymer, wherein the monomer used to form the polymer consists of methoxymethyl acrylate, methoxyethyl acrylate (MEA), ethoxymethyl acrylate, ethoxyethyl acrylate, methoxymethyl methacrylate, methoxyethyl methacrylate, ethoxymethyl methacrylate, ethoxyethyl methacrylate, or a combination thereof.
US Pat. No. 10,193,134

DOPED SODIUM MANGANESE OXIDE CATHODE MATERIAL FOR SODIUM ION BATTERIES

UMICORE, Brussels (BE) U...

1. A sodium transition metal cathode material for a rechargeable sodium battery, having a P2 layered bronze crystal structure and having a composition NaxMO2, M comprising at least 55 mol % manganese, wherein the manganese valence state is at least 3.75, wherein 2/3
US Pat. No. 10,193,138

GLASS-FIBER CONTAINING COMPOSITE MATERIALS FOR ALKALI METAL-BASED BATTERIES AND METHODS OF MAKING

Johns Manville, Denver, ...

1. A method of making a glass-fiber composite, the method comprising the steps of:forming a wet laid non-woven glass fiber substrate, wherein the glass fiber substrate comprises a sodium-based compound selected from the group consisting of NaMnO2; NaNiO2; Na(Ni0.5Mn0.5)O2, NaFePO4, Na2Fe2(SO4)3, and Na2Mn11[Mn11(CN)6]; and contacting alkali-metal containing particles on the substrate.
US Pat. No. 10,189,808

SOLID FORMS OF 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-5-YL)METHYL)-2,2-DIFLUOROACETAMIDE, AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES

Celgene Corporation, Sum...

1. A solid form of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a tautomer thereof, which is Form C having an X-ray powder diffraction pattern comprising peaks at about 16.7, 16.9, 17.7 or 24.7 degrees 2?.
US Pat. No. 10,193,143

NEGATIVE ELECTRODE ACTIVE MATERIAL FOR ELECTRICITY STORAGE DEVICES AND METHOD FOR PRODUCING SAME

NIPPON ELECTRIC GLASS CO....

1. A negative electrode active material for an electricity storage device, comprising a composition containing TiO2, Na2O, and a network-forming oxide, and comprising a precipitated crystal of a monoclinic crystal containing Na, Ti, and O.
US Pat. No. 10,189,811

METHOD FOR PREPARING THE ANHYDROUS CRYSTALLINE FORM OF ISONIAZID-DERIVED HYDRAZONE, THUS PRODUCED CRISTALLINE POLYMORPH OF THE ANHYDROUS FORM, USE THEREOF FOR THE TREATMENT OF ALZHEIMER'S DISEASE, PARKINSONISM AND OTHER NEURODEGENERATIVE DISORDERS, AND PH


US Pat. No. 10,190,071

STABILIZED BLENDS CONTAINING FRICTION MODIFIERS

The Lubrizol Corporation,...

1. A composition comprising:(a) a medium comprising a solvent, a functional fluid, an additive concentrate or combinations thereof; and
(b) a friction modifier component comprising a condensation product of tartaric and/or citric acid and a linear or branched fatty alcohol of 10 to 18 carbon atoms wherein said condensation product is not fully soluble in the medium; and
(c) a stabilizing component comprising a dispersant that is soluble in (a) and that interacts with (b) such that the solubility of (b) in (a) is improved, wherein said stabilizing component is present at about 4% to about 8% by weight of said composition;
wherein component (b) is present in component (a) in the form of dispersed particles wherein no more than 10 percent by weight of the particles have a diameter of more than 0.5 microns;
wherein component (b) is present in the overall composition at a level of 2 to 4 percent by weight;
wherein component (c), the stabilizing component, comprises: (i) a nitrogen-containing dispersant comprising a reaction product of a hydrocarbyl-substituted succinic acylating agent and a polyamine; (ii) a borated nitrogen-containing dispersant comprising a reaction product of a hydrocarbyl-substituted succinic acylating agent and a polyamine which is borated; (iii) an alkyl imidazoline derived from a polyalkylene amine and a fatty mono-carboxylic acid; or combinations thereof;
wherein a N:CO ratio of (i) or (ii) ranges from greater than 1.3:1 to about 2:1; and
wherein a TBN, as defined by ASTM D4739, of (iii) is greater than 9.
US Pat. No. 10,190,072

METHOD FOR IMPROVING ENGINE FUEL EFFICIENCY

EXXONMOBIL RESEARCH AND E...

1. A method for improving fuel efficiency and reducing frictional properties, while maintaining or improving deposit control, in an engine lubricated with a lubricating oil by using as the lubricating engine oil a formulated oil, said formulated oil having a composition comprising:from 75 to 95 wt % of lubricating oil base stock selected from the group consisting of a Group I base stock, a Group II base stock, a Group III base stock, a Group IV base stock, a Group V base stock and combinations thereof;
a friction modifier mixture comprising a polymeric ethoxylated fatty acid ester having a molecular weight of greater than or equal to 2000 at from 0.1 to 1.0 wt. % of the weight of the lubricating engine oil and an organic molybdenum containing friction modifier contributing from 80 ppm to 500 ppm of elemental molybdenum based on the weight of the lubricating engine oil, and
an overbased calcium salicylate detergent contributing from 200 ppm to 2000 ppm of elemental calcium based on the weight of the lubricating engine oil;
wherein the remainder of the lubricating engine oil includes one or more other lubricating oil additives;
wherein fuel efficiency and friction reduction properties are improved (mini-traction machine (MTM) in Stribeck mode friction coefficient at 140° C. less than or equal to 0.20) and deposit control is maintained or improved (TEOST 33C total deposits less than or equal to 30 mg) as compared to friction reduction properties and deposit control achieved using the same lubricating engine oil not containing the friction modifier mixture and the overbased calcium salicylate detergent.
US Pat. No. 10,189,818

5-(5-(2-(3-AMINOPROPDOXY)-6-METHOXYPHENYL)-1H-PYRAZOL-3-YLAMINO)PYRAZINE-2-CARBONITFILE (S)-LACTATE MONOHYDRATE

Eli Lilly and Company, I...

1. A compound which is 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile (S)-lactate monohydrate.
US Pat. No. 10,192,641

METHOD OF GENERATING A DYNAMIC PATHWAY MAP

The Regents of the Univer...

1. A processor-based method of generating a dynamic pathway map (DPM), comprising:accessing a model database that stores a probabilistic pathway model that comprises a plurality of pathway elements;
assigning an influence level for at least one pathway of a first number of the plurality of pathway elements on the basis of known attributes;
cross correlating the first number of the plurality of pathway elements;
assigning an influence level for at least one pathway on the basis of assumed attributes;
measuring a patient sample to identify measured attributes of the patient sample, based on a genome-scale assay;
modifying the probabilistic pathway model by using a plurality of the measured attributes for a plurality of elements of the patient sample, via an analysis engine, the modifying comprising:
obtaining a factor graph representing states of entities in a cell and interactions between the entities, wherein the factor graph encodes a state of the cell using a random variable for each entity and wherein the factor graph has reference pathway activity information for a particular pathway, the reference pathway indicating deviations from the probabilistic pathway model; and
formulating a treatment option for the patient based on the reference pathway activity of the factor graph, wherein at least one of the above method operations is performed through a processor.
US Pat. No. 10,191,365

REFLECTIVE MASK BLANK, METHOD OF MANUFACTURING REFLECTIVE MASK BLANK, REFLECTIVE MASK AND METHOD OF MANUFACTURING SEMICONDUCTOR DEVICE

HOYA CORPORATION, Shinju...

1. A reflective mask blank, comprising:a mask blank multilayer film that comprises a multilayer reflective film obtained by alternately laminating a high refractive index layer and a low refractive index layer, and
an absorber film on or above a main surface of a mask blank substrate;
wherein, the root mean square roughness (Rms), obtained by measuring a 3 ?m ×3 ?m region on a surface of the reflective mask blank on which the mask blank multilayer film is formed with an atomic force microscope, is not more than 0.5 nm and an integrated value of a power spectrum density at a spatial frequency of 1 ?m?1 to 10 ?m?1 is not more than 800×10?3 nm3.
US Pat. No. 10,190,086

METHODS OF PITCHING YEAST FOR FERMENTATION, AND RELATED METHODS OF FERMENTATION AND SYSTEMS

POET Research, Inc., Sio...

1. A method of pitching yeast for fermentation, the method comprising:providing a first aqueous composition in a first fermentation reactor, wherein the first aqueous composition comprises:
yeast;
a slurry comprising water and a processed plant material comprising an amount of at least one monosaccharide; wherein the processed plant material comprises corn flour and the slurry further comprises one or more enzymes that can break down starch in the corn flour into glucose;
fermenting the first aqueous composition in the first fermentation reactor to form a first beer composition comprising alcohol;
providing a fraction of the first beer composition to a second fermentation reactor, wherein the first beer composition in the first fermentation reactor comprises an alcohol at a concentration of at least 15 percent by volume when the fraction of the first beer composition is removed from the first fermentation reactor, and wherein the fraction of the first beer composition comprises a fraction of the yeast and the alcohol;
combining a slurry with the fraction of the first beer composition in the second fermentation reactor to form a second aqueous composition in the second fermentation reactor, wherein the slurry comprises water and a processed plant material comprising an amount of at least one monosaccharide; wherein the processed plant material comprises corn flour and the slurry further comprises one or more enzymes that can break down starch in the corn flour into glucose; and
distilling the first beer composition from the first fermentation reactor to recover alcohol.
US Pat. No. 10,191,366

ETCH VARIATION TOLERANT OPTIMIZATION

ASML Netherlands B.V., V...

1. A method to improve a lithographic process for imaging a portion of a design layout onto a substrate using a lithographic projection apparatus and for transferring the imaged portion of the design layout to the substrate by an etching process, the method comprising:determining a value of an evaluation point of the lithographic process for each of a plurality of variations of the etching process;
computing, by a hardware computer system, a multi-variable cost function of a plurality of design variables that are characteristics of the lithographic process, wherein the multi-variable cost function is a function of a deviation from the determined values of the evaluation point; and
reconfiguring one or more of the characteristics of the lithographic process by adjusting one or more of the design variables and re-evaluating the cost function, until a termination condition for the cost function is satisfied.
US Pat. No. 10,191,371

UNDERLAYER COMPOSITION AND METHOD OF IMAGING UNDERLAYER

ROHM AND HAAS ELECTRONIC ...

1. An underlayer comprising:an acid sensitive copolymer comprising:
an acid decomposable group;
an attachment group; and
a functional group; and
a photoacid generator,
where the functional group is operative to adjust neutrality of the acid-sensitive copolymer relative to a self-assembling block copolymer that is to be disposed on the underlayer, where the neutrality means that a surface energy of the underlayer is substantially the same as that of at least one block of the block copolymer;
wherein the attachment group is covalently bonded to a hydrophilic surface of a substrate by alkoxide linkages where the attachment group comprises a thiol, a primary or secondary amine substituted, a straight chain or branched C1-30 alkyl, a C3-30 cycloalkyl, a C6-30 aryl, a C7-30 alkaryl, a C7-30 aralkyl, a C1-30 heteroalkyl, a C3-30 heterocycloalkyl, a C6-30 heteroaryl, a C7-30 heteroalkaryl, a C7-30 heteroaralkyl, or a combination comprising at least one of these groups; and wherein the acid decomposable groups are ester groups, acetal groups, ketal groups, or pyrocarbonate groups.
US Pat. No. 10,190,092

PROCUREMENT OF PLACENTAL STEM CELLS

1. A method for collecting stem cells from a placenta obtained after childbirth, the method comprising:draining cord blood from the placenta obtained after childbirth;
collecting the drained cord blood in a first collection;
infusing the drained placenta with a first solution, the first solution consisting of a placental preservative base solution and prostaglandin, wherein the placental preservative base solution consists of NaCl, KCl, glucose, citric acid, adenine, histidine, glutamate, glutathione, and N-acetyl-L-cysteine;
infusing the placenta with a second solution before the first solution is collected, the second solution consisting of said placental preservative base solution, a stem cell releasing agent, an antibiotic, and an anticoagulant, wherein the stem cell releasing agent is 1, 1?-[1,4-phenylenebis (methylene)]-bis-1,4,8,11-tetraazacyclotetradecane or a pharmaceutically acceptable salt thereof;
waiting for a predetermined amount of time as the first and second solutions perfuse the placenta, wherein said predetermined amount of time is 5 minutes or fewer; and
collecting, in a second collection, said first and second solutions from the placenta, wherein the collected first and second solutions comprise stem cells from the placenta.
US Pat. No. 10,191,373

METHOD FOR PRODUCING POLYMER

SHIN-ETSU CHEMICAL CO., L...

1. A method for producing a polymer comprising recurring units having an acid generator bound to the backbone, comprisingpolymerizing monomers corresponding to the recurring units in a solution of a non-polymerizable compound containing at least one nitrogen atom to which at least one acid labile group is bound.
US Pat. No. 10,190,094

METHODS AND COMPOSITIONS RELATED TO INDUCED SENSORY NEURONS

The Scripps Research Inst...

1. A method for generating induced sensory neurons (iSNs), comprising co-expressing Brn3A and Ngn1 genes via one or more expression vectors harboring Brn3A and Ngn1 genomic or cDNA sequences in a non-neuronal cell, thereby generating induced sensory neurons, wherein the non-neuronal cell is a fibroblast or a stem cell from a mammal.
US Pat. No. 10,193,171

FUEL CELL WITH INTEGRATED WATER MANAGEMENT LAYER AND FABRICATION METHOD THEREOF

1. Fabrication method of a fuel cell comprising the following successive steps:providing a substrate comprising:
at least one membrane-electrode assembly, formed by an electrolytic membrane arranged between a first electrode and a second electrode,
a first current collector arranged on the first electrode,
depositing a fluoropolymer solution on the first current collector,
making a solvent of the fluoropolymer solution evaporate so as to form a porous thin layer of fluoropolymer.
US Pat. No. 10,190,095

MYELINATION OF CONGENITALLY DYSMYELINATED FOREBRAINS USING OLIGODENDROCYTE PROGENITOR CELLS

Cornell Research Foundati...

1. An in vitro method of obtaining human oligodendrocyte progenitor cells, said method comprising:providing a mixed population containing human brain or spinal cord cell types;
removing neurons and neuronal progenitor cells expressing polysialylated N-CAM (PSA-NCAM) from the mixed population to produce a treated mixed population; and
removing the oligodendrocyte progenitor cells expressing A2B5 from the treated mixed population to form an enriched population of A2B5+/PSA-NCAM? oligodendrocyte progenitor cells.
US Pat. No. 10,190,096

METHODS FOR GENERATING STEM CELL-DERIVED ? CELLS AND USES THEREOF

President and Fellows of ...

1. A method for generating stem cell-derived ? (SC-?) cells, the method comprising contacting a cell population comprising endocrine progenitor cells under conditions suitable to direct differentiation of said endocrine progenitor cells into said SC-? cells with an effective amount of an agent that decreases the level and/or activity of c-Jun N-terminal kinase (JNK), thereby generating said SC-? cells, wherein the endocrine progenitor cells comprise PDX1+/NKX6.1+/NEUROD1+/insulin+/glucagon?/somatostatin? cells.
US Pat. No. 10,190,097

METHOD AND COMPOSITION FOR INDUCING HUMAN PLURIPOTENT STEM CELLS

The Regents of the Univer...

1. A method of pluripotency reprogramming, comprising:treating a human cell with a cell culture medium comprising fibromodulin (FMOD) for a period ranging from a day to a month, and
changing the cell culture medium regularly until a FMOD reprogrammed (FreP) cell forms;
wherein the FreP cell expresses NANOG and does not form teratoma, and
wherein the human cell is a fibroblastic cell.
US Pat. No. 10,192,661

R—T—B BASED SINTERED MAGNET

TDK CORPORATION, Tokyo (...

1. A R-T-B based sintered magnet, wherein:R contains Y and R1,
Y is yttrium,
R1 is at least one rare earth element except Y but contains Nd, and
T represents at least one transition metal element containing Fe or a combination of Fe and Co,
a ratio of R1 to Y (R1:Y) in a grain boundary phase is 73:27 to 55:45 in terms of a calculated molar ratio of the grain boundary phase.
US Pat. No. 10,188,052

MAIZE PLANTS WITH IMPROVED PATHOGEN RESISTANCE

Monsanto Technology LLC, ...

1. A method of obtaining a corn plant with improved tar spot complex (TARSC) resistance, said method comprising:a) providing a population of corn plants;
b) obtaining at least one DNA sample from at least one plant within said population;
c) detecting in the DNA sample the presence of a TARSC resistance allele comprising a “T” at nucleotide position 61 of SEQ ID NO: 6 in, or genetically linked to, a chromosomal segment between about 3.99 cM and about 17.7 cM on chromosome 10;
d) selecting one or more plants from said population based on the presence of said allele;
e) crossing at least one selected plant comprising said allele with a second corn plant that comprises one or zero TARSC resistance alleles to produce one or more progeny plants that produce seeds;
f) collecting the seeds produced by the one or more progeny plants; and
g) growing from said seeds at least one plant having said allele and having improved TARSC resistance.
US Pat. No. 10,190,103

POLYPEPTIDES HAVING GLUCURONYL ESTERASE ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME

1. A method for degrading or hydrolyzing a cellulosic material, comprising: contacting the cellulosic material with an enzyme composition and an isolated polypeptide having glucuronyl esterase activity to thereby degrade or hydrolyze the cellulosic material, wherein the isolated polypeptide having glucuronyl esterase activity is selected from the group consisting of:(a) a polypeptide comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of amino acids 101 to 474 of SEQ ID NO: 2;
(b) a polypeptide encoded by a polynucleotide that hybridizes under high stringency conditions with the full-length complement of the nucleotide sequence of nucleotides 33 to 1457 of SEQ ID NO: 1, wherein the high stringency conditions are defined as prehybridization and hybridization at 42° C. in 5×SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and 50% formamide, and washing three times each for 15 minutes using 2×SSC, 0.2% SDS at 65° C.;
(c) a polypeptide encoded by a polynucleotide comprising a nucleotide sequence having at least 90% sequence identity to the nucleotide sequence of nucleotides 33 to 1457 of SEQ ID NO: 1; and
(d) a fragment of the amino acid sequence of amino acids 101 to 474 of SEQ ID NO: 2, wherein the fragment has glucuronyl esterase activity.
US Pat. No. 10,188,053

HYBRID TOMATO VARIETY 72-195 RZ

RIJK ZWAAN ZAADTEELT EN Z...

1. A Solanum lycopersicum plant designated 72-195 RZ, representative seed of which having been deposited under NCIMB Accession No. 42734.
US Pat. No. 10,190,104

ISOFORM OF ANAPLASTIC LYMPHOMA KINASE AND ITS USES

Memorial Sloan Kettering ...

1. An isolated complementary DNA (cDNA) molecule comprising the nucleic acid sequence of exons 20-29 and a portion of intron 19 of an Anaplastic Lymphoma Kinase (ALK) gene, wherein the cDNA molecule does not comprise the nucleic acid sequence of exons 1-19 of the ALK gene, either individually or in any combination and wherein the portion of intron 19 of the ALK gene is about 400 bp in length located upstream of exon 20 of the ALK gene.
US Pat. No. 10,188,054

HYBRID TOMATO VARIETY 72-191 RZ

RIJK ZWAAN ZAADTEELT EN Z...

1. A Solanum lycopersicum plant designated 72-191 RZ, representative seed of which having been deposited under NCIMB Accession No. 42733.
US Pat. No. 10,190,105

HBV POLYMERASE MUTANTS

Transgene S.A., Illkirch...

1. A mutant polypeptide which comprises a mutated HBV polymerase domain with an internal deletion that functionally disrupts the polymerase activity, wherein said internal deletion is of at least 4 amino acid residues and at most 30 amino acid residues, wherein said mutated polymerase domain comprises the amino acid sequence shown in SEQ ID NO:1 but lacks at least the Tyr residue in position 203, the Met residue in position 204, the Asp residue in position 205 and the Asp residue in position 206, the Val residue in position 207, the Val residue in position 208, and the Leu residue in position 209.
US Pat. No. 10,193,183

NONAQUEOUS ELECTROLYTE SECONDARY BATTERIES

SANYO Electric Co., Ltd.,...

1. A nonaqueous electrolyte secondary battery comprising a positive electrode including a lithium transition metal oxide, a negative electrode including a negative electrode active material capable of storing and releasing lithium ions, and a nonaqueous electrolyte,the negative electrode active material including a carbon material as a main component,
the negative electrode including a lithium tungsten composite oxide and/or a lithium molybdenum composite oxide.
US Pat. No. 10,188,056

HYBRID TOMATO VARIETY 72-762 RZ

RIJK ZWAAN ZAADTEELT EN Z...

1. A Solanum lycopersicum tomato plant designated 72-762 RZ, representative seed of which having been deposited under NCIMB Accession No. 42810.
US Pat. No. 10,188,058

SWEET CORN HYBRID SVSK6143 AND PARENTS THEREOF

Seminis Vegetable Seeds, ...

1. A corn plant comprising at least a first set of the chromosomes of corn line SHY-6S15-9078LP or corn line SHY-6RHBE322, a sample of seed of said lines having been deposited under ATCC Accession Number PTA-124211 and ATCC Accession Number PTA-124212, respectively.
US Pat. No. 10,188,059

SOYBEAN VARIETY 5PUWT62

MONSANTO TECHNOLOGY LLC, ...

1. A plant of soybean variety 5PUWT62, wherein a sample of seed of said variety has been deposited under ATCC Accession No. PTA-125158.
US Pat. No. 10,190,110

ENGINEERED BOTULINUM NEUROTOXIN

PRESIDENT AND FELLOWS OF ...

1. A nucleic acid comprising a nucleotide sequence that encodes a polypeptide comprising a modified receptor binding domain of Clostridial botulinum serotype B, wherein the modified receptor binding domain comprises an amino acid substitution of M, Q, T or I at the amino acid position E1191 of the polypeptide of SEQ ID NO: 4, wherein the substitution produces enhanced binding of the modified receptor binding domain to human Syt II as compared to an identical molecule lacking the substitution.
US Pat. No. 10,188,060

SOYBEAN CULTIVAR S170005

M.S. Technologies, LLC, ...

1. A plant of soybean cultivar S170005, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124455.
US Pat. No. 10,190,111

ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME

Portola Pharmaceuticals, ...

1. An isolated two-chain polypeptide comprising:1) a first chain comprising amino acid residues 1-105 of SEQ ID NO: 22, and
2) a second chain comprising amino acid residues 112-365 of SEQ ID NO: 22,
wherein the two-chain polypeptide (a) has reduced catalytic activity as compared to the corresponding wild-type factor Xa protein, (b) is capable of binding to a factor Xa inhibitor and (c) cannot assemble into a prothrombinase complex.
US Pat. No. 10,188,061

SOYBEAN VARIETY 01064486

Monsanto Technology LLC, ...

1. A plant of soybean variety 01064486, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124958.
US Pat. No. 10,190,112

METHOD FOR THE BIOCATALYTIC CYCLIZATION OF TERPENES AND CYCLASE MUTANTS EMPLOYABLE THEREIN

BASF SE, Ludwigshafen am...

1. An enzyme mutant with cyclase activity which is a mutant of a wild-type enzyme comprising the amino acid sequence of SEQ ID NO: 209 with a mutation at a position corresponding to position F445 of the amino acid sequence of SEQ ID NO: 209, wherein up to 10% of the amino acid residues in said enzyme mutant are altered relative to the amino acid sequence of SEQ ID NO: 209 by deletion, insertion, substitution, addition, inversion, or a combination thereof, and wherein said enzyme mutant catalyzes at least the cyclization of a citronellal isomer to at least one isopulegol isomer.
US Pat. No. 10,188,062

SOYBEAN CULTIVAR S170037

M.S. Technologies, LLC, ...

1. A plant of soybean cultivar S170037, representative seed of said soybean cultivar having been deposited under ATCC Accession No. PTA-124480.
US Pat. No. 10,190,113

METHODS AND COMPOSITIONS FOR SEGREGATING TARGET NUCLEIC ACID FROM MIXED NUCLEIC ACID SAMPLES

FLIR DETECTION, INC., St...

1. A method for enriching a target nucleic acid in a mixed sample containing the target nucleic acid and a non-target nucleic acid, comprising:(i) digesting the mixed sample with a methylation-sensitive or methylation-dependent endonuclease that cleaves the target nucleic acid and not the non-target nucleic acid;
(ii) digesting the sample with an endonuclease; wherein the endonuclease cleaves the non-target nucleic acid and not the target nucleic acid, resulting in non-target nucleic acid ends that do not bind to the cleaved target nucleic acid;
(iii) circularizing the cleaved target nucleic acid; wherein the circularized target nucleic acid is resistant to digestion with DNase or exonuclease; and
(iv) depleting the non-target nucleic acid.
US Pat. No. 10,188,064

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH246236

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH246236, produced by crossing a first plant of variety CV462675 with a second plant of variety CV507905, wherein representative seeds of said varieties CV462675 and CV507905 are deposited under ATCC Accession Nos. PTA-124501 and PTA-123822, respectively.
US Pat. No. 10,190,115

METHODS AND COMPOSITIONS FOR NUCLEIC ACID ANALYSIS

Bio-Rad Laboratories, Inc...

1. A composition comprising a plurality of second partitions containing first partitions, wherein:a. said first partitions are degradable upon the application of a stimulus to said first partitions such that contents of a first partition is mixed with contents of a second partition; and
b. said first partitions are contained within the second partitions;
c. said first partitions contain an oligonucleotide barcode; and
d. the first partitions have on average a first average volume and the second partitions have on average a second average volume, wherein the second average volume is at least twice as large as the first average volume.
US Pat. No. 10,189,859

DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE

Nektar Therapeutics, San...

1. A 6-(2,3-dichlorophenyl)-1,2,4-triazine-5 amine compound having an N-bonded substituent at the 3-position of the triazine ring and an amino (—NH2) group at the 5-position of the triazine ring, wherein the N-bonded substituent is an amino nitrogen covalently attached to the 3-carbon of the triazine ring, wherein the amino nitrogen forms part of a substituted or unsubstituted nitrogen-containing heterocycle selected from the group consisting of a substituted or unsubstituted piperazine, a substituted or an unsubstituted pyrrolidine, a substituted or an unsubstituted azetidine, and a substituted or an unsubstituted diazetidine, where any of the foregoing nitrogen-containing heterocycles may form part of a bi- or a tricylic ring structure,wherein a substituted nitrogen-containing heterocycle comprises one or more substituents, where the substituent is a linear or a branched alkyl chain, and/or comprises an oligomeric ethylene oxide chain, which may be further substituted with one or more functional groups selected from C1-C6 alkyl ether, amino, hydroxyl, carboxyl, aldehyde, alkylsulfone, tetrazole, oxetane, C2-C6 carbonate ester, alkyl ester, alkylsulfoxide, halo, amido, sulfonamide, cycloalkyl, heterocyclyl, —CF3, —CF2H, and —CFH2, and wherein the dichlorophenyl ring may possess an additional substituent at any one of positions 4, 5 or 6,
or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,188,066

MAIZE HYBRID X03M280

PIONEER HI-BRED INTERNATI...

1. A seed of hybrid maize variety X03M280, representative seed produced by crossing a first plant of variety PH42YG with a second plant of variety PH2DPY, wherein representative seed of the varieties PH42YG and PH2DPY have been deposited under ATCC Accession Numbers PTA-124780 and PTA-124001, respectively.
US Pat. No. 10,188,067

MAIZE HYBRID X08M611

PIONEER HI-BRED INTERNATI...

1. A seed of hybrid maize variety X08M611, representative seed produced by crossing a first plant of variety PH41R5 with a second plant of variety PH4257, wherein representative seed of the varieties PH41R5 and PH4257 have been deposited under ATCC Accession Numbers PTA-124793 and PTA-124803, respectively.
US Pat. No. 10,191,398

ELECTROPHOTOGRAPHIC PHOTOCONDUCTOR, IMAGE FORMING APPARATUS, AND PROCESS CARTRIDGE

Ricoh Company, Ltd., Tok...

8. An electrophotographic photoconductor, comprising:a conductive support having a volume resistivity of 1×1010?·cm or less;
an undercoat layer; and
a photoconductive layer,
wherein the undercoat layer and the photoconductive layer being disposed on the conductive support in an order mentioned,
wherein the undercoat layer comprises:
zinc oxide particles;
a urethane bond-containing resin; and
methylethyl ketone oxime,
wherein an amount of the methylethyl ketone oxime included in the undercoat layer is from 2,888 ppm to 5,000 ppm, and
wherein the undercoat layer satisfies a formula below:
10 where M is a ratio (ppm) of the methylethyl ketone oxime comprised in the undercoat layer, and L is an average thickness (?m) of the undercoat layer.
US Pat. No. 10,188,068

MAIZE HYBRID X08M612

PIONEER HI-BRED INTERNATI...

1. A seed of hybrid maize variety X08M612, representative seed produced by crossing a first plant of variety PH41V8 with a second plant of variety PH2SRH, wherein representative seed of the varieties PH41V8 and PH2SRH have been deposited under ATCC Accession Numbers PTA-124794 and PTA-124300, respectively.
US Pat. No. 10,190,119

MITOCHONDRIAL PHOSPHATE CARRIER TARGETS FOR TREATING SOFT-TISSUE CALCIFICATION

1. A method of treating soft-tissue calcification in a coronary artery or heart valve in a subject, the method comprising administering a therapeutically-effective amount of an inhibitor of solute carrier family 25 member 24 (SLC25A24) to the subject, wherein the SLC25A24 inhibitor comprises at least one small interfering RNA (siRNA) comprising a targeting sequence selected from the group consisting of: CAGAUGAAUUCACGGAAGA (SEQ ID NO: 1), GCAUAUGAACAGUACAAGA (SEQ ID NO: 2), GGAAAUGGUACAAACGUCA (SEQ ID NO: 3), and GGUGCUGUCUCUCGAACAA (SEQ ID NO: 4) wherein the SLC25A24 inhibitor decreases the expression level of SCL25A24.
US Pat. No. 10,190,631

SLIDING ENGINE COMPONENT

Mahle International GmbH,...

8. A sliding engine component according to claim 1, further comprising a plastic polymer-based layer that does not contain a thermochromic material, which is disposed between the metallic substrate and the sliding surface.
US Pat. No. 10,188,072

SOYBEAN VARIETY 01064694

Monsanto Technology LLc, ...

1. A plant of soybean variety 01064694, wherein representative seed of said soybean variety have been deposited under ATCC Accession No. PTA-124971.
US Pat. No. 10,188,074

SOYBEAN VARIETY 5PKCF87

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PKCF87, representative seed of the variety having been deposited under ATCC Accession Number PTA-125527.
US Pat. No. 10,188,075

SOYBEAN VARIETY 5PKDS07

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PKDS07, representative seed of the variety having been deposited under ATCC Accession Number PTA-125528.
US Pat. No. 10,188,589

DEPOSITION OF HYDROPHOBIC ACTIVES IN THE PRESENCE OF SURFACTANTS

Dow Global Technologies L...

1. A personal care composition, comprising:an anionic surfactant; and
a polyurea shell encapsulating a hydrophobic personal care active selected from the group consisting of a fragrance, a vitamin, an extract, or a therapeutic active, wherein the polyurea shell has at least one covalently attached cationic polymer, selected from the group consisting of quaternary amines and cationic biopolymers, wherein the polyurea shell has at least one covalently attached quaternary amine that is the reaction product of (2-Aminoethyl) trimethylammonium chloride and polyisocyanate.
US Pat. No. 10,189,871

TRANSITION METAL COMPLEXES FOR ENANTIOSELECTIVE CATALYSIS OF CARBON-CARBON, CARBON-HETEROATOM, AND CARBON-HYDROGEN BOND FORMING REACTIONS

1. A compound, comprising a transition metal complex having the formula ?-[M ((x,y)-L1)3?b?c((w,v)-L2)b((t,u)-L3)c]p+An?m,Z?p?m, wherein ? is ? or ?, wherein M is a transition metal, wherein p is an integer corresponding to the oxidation state of M, wherein each of x, y, w, v, t, and u independently comprises one of R and S, wherein each of L1 and L2 independently is a ligand comprising ethylene diamine, wherein L3 is EN(CH2)nNR1R2, wherein EN represents ethylene diamine, wherein n is from 2 to 4, and wherein R1 and R2 are independently H or alkyl groups, wherein c is from 1 to 3, wherein b is from 0 to 2, wherein An? comprises a lipophilic anion, wherein m is from 1 to 3, and wherein Z? comprises a second anion.
US Pat. No. 10,190,128

KITS COMPRISING PLUS-SENSE SINGLE STRANDED RNA VIRAL VECTORS AND METHODS FOR PRODUCING POLYPEPTIDES USING THE KITS

1. A kit comprisinga) a first plus-sense single stranded ribonucleic acid (RNA) viral vector, and
b) a second plus-sense single stranded RNA viral vector,
wherein
(i) the first plus-sense single-stranded viral vector and the second plus-sense single-stranded viral vector are derived from different plant viruses, and
(ii) the coat protein open reading frame (ORF) of the virus from which the first vector is derived is completely deleted in the first plus-sense single stranded RNA viral vector, and
(iii) the coat protein ORF of the virus from which the second vector is derived is completely deleted in the second plus-sense single stranded RNA viral vector, and
(iv) the first plus-sense single stranded RNA viral vector comprises a functional coat protein ORF of the virus from which the second plus-sense single-stranded viral vector is derived, and
(v) the second plus-sense single stranded RNA viral vector comprises a functional coat protein ORF of the virus from which the first plus- sense single-stranded viral vector is derived, and
(vi) the first plus-sense single-stranded viral vector and the second plus-sense single-stranded viral vector comprise an RNA replicon which is able to replicate in plant cells,
and wherein
the virus from which the first plus-sense single-stranded viral vector is derived is a Potexvirus, and
the virus from which the second plus-sense single-stranded viral vector is derived is a Tobamovirus.
US Pat. No. 10,188,591

METHOD OF ENHANCING HAIR GROWTH

ALLERGAN, INC., Irvine, ...

1. A method of growing eyebrow hair, comprising applying on at least one eyebrow an effective amount of a topical composition containing bimatoprost or a pharmaceutically-acceptable salt thereof.
US Pat. No. 10,190,129

INCREASING LEVELS OF NICOTINIC ALKALOIDS IN PLANTS

22nd Century Limited, LLC...

1. A method for increasing nicotine and yield in a Nicotiana plant, comprising:(a) crossing an increased nicotine Nicotiana plant that expresses heterologous NBB1 having the amino acid sequence set forth in SEQ ID NO: 2 and A622 having the amino acid sequence set forth in SEQ ID NO: 4 with a high yielding Nicotiana plant; and
(b) selecting progeny plant with increased nicotine and high yield, wherein the plant has an increased nicotine content and yield relative to a non-transformed control plant.
US Pat. No. 10,190,130

POLYSACCHARIDE SYNTHASES

The University of Melbour...

1. A method for decreasing the level of (1,3;1,4)-?-D-glucan produced by a plant or fungal cell, the method comprising decreasing the level and/or activity of a CslF-encoded (1,3;1,4)-?-D-glucan synthase in the cell, wherein the level and/or activity of the CslF-encoded (1,3;1,4)-?-D-glucan synthase is decreased by decreasing the expression of a CslF nucleic acid in the cell, and wherein decreasing the expression of a CslF nucleic acid in the cell results in a decrease of the level of (1,3;1,4)-?-D-glucan produced by the cell compared to a wild-type cell of the same taxon, and wherein the CslF nucleic acid comprises:(i) a nucleotide sequence set forth in SEQ ID NO: 1;
(ii) a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO: 2; or
(iii) a nucleotide sequence encoding an amino acid sequence which is at least 90% identical to the amino acid sequence set forth in SEQ ID NO: 2.
US Pat. No. 10,189,874

DNA GRIDIRON COMPOSITIONS AND METHODS

Arizona Board of Regents ...

1. A composition, comprising:a plurality of immobile Holliday junction analogs wherein each junction comprises a 60° torsion angle linked together in a square frame having at least two layers in which the helices on opposite sides lie in the same plane, and wherein said plurality of immobile Holliday junction analogs are linked together with a central strand of single-stranded DNA within said square frame.
US Pat. No. 10,188,595

MULTI-PURPOSE COSMETIC COMPOSITIONS

Mary Kay Inc., Addison, ...

1. A method for treating the skin of a subject in need thereof comprising topically applying to the skin of said subject a cosmetic composition that includes effective amounts of a Silybum marianum extract and a Momordica grosvenori fruit extract, wherein the Silybum marianum extract is a hydroalcoholic extract and the Momordica grosvenori fruit extract is a hydroglycolic extract.
US Pat. No. 10,190,133

COMPOSITIONS AND METHODS FOR IMPROVING ABIOTIC STRESS TOLERANCE

China Agricultural Univer...

1. A recombinant nucleic acid, comprising:(a) the nucleotide sequence SEQ ID NO:1; or
(b) a nucleotide sequence that encodes a polypeptide comprising the amino acid sequence SEQ ID NO:28,
wherein each of the nucleotide sequences of (a) and (b) is operably linked to a heterologous promoter.
US Pat. No. 10,190,134

COMPOSITIONS AND METHODS FOR INSECTICIDAL CONTROL OF STINKBUGS

E I DU PONT DE NEMOURS AN...

1. An expression cassette, comprising a heterologous promoter operably linked to a polynucleotide encoding a double stranded RNA, wherein the double stranded RNA comprises the sense and antisense sequence of a nucleotide sequence selected from the group consisting of:(a) a nucleotide sequence comprising any one of SEQ ID NOS: 9, or 30-34;
(b) a nucleotide sequence comprising at least 95% sequence identity to any one of SEQ ID NOS: 9, or 30-34; and
(c) a nucleotide sequence comprising at least 23 consecutive nucleotides of any one of SEQ ID NOS: 9, or 30-34;
wherein said double stranded RNA has insecticidal activity against a Pentatomidae plant pest.
US Pat. No. 10,189,878

EBOLAVIRUS PRE-HAIRPIN INTERMEDIATE MIMICS AND METHODS OF USE

University of Utah Resear...

1. An Ebolavirus N-trimer mimic comprising a homotrimer of peptide monomers, wherein each peptide monomer comprises an an amino acid sequence of SEQ ID NO:23 or SEQ ID NO:21.
US Pat. No. 10,190,136

MOUSE MODEL OF ALPHA-ONE ANTITRYPSIN (AAT) DEFICIENCY

University of Massachuset...

1. A transgenic mouse whose genome comprises inactivating mutations in exon 2 of each of Serpina1a, Serpina1b, Serpina1c, Serpina1d, and Serpina1e genes, and which expresses no hepatic or circulatory Alpha-One Antitrypsin (AAT) protein.
US Pat. No. 10,190,649

FRICTION MATERIAL

AKEBONO BRAKE INDUSTRY CO...

1. A friction material comprising:a fiber base material;
a friction modifier; and
a binder,
wherein a content of copper is 0.5% by mass or less in terms of copper element,
wherein a content of the binder is 10% by mass or more,
wherein the friction material contains calcium hydroxide and zinc,
wherein the friction material has pH of 113 or more,
wherein a content of the zinc is from 1% by mass to 5% by mass,
wherein the zinc comprises a powder having an average particle diameter in a range of 1 ?m to 10 ?m,
wherein the calcium hydroxide comprises powder having an average particle diameter in a range of 5 ?m to 50 ?m,
wherein the fiber base material comprises a bio-soluble inorganic fiber, and
wherein the binder consists of at least one selected from the group consisting of an acrylic rubber-modified phenol resin, a silicone rubber-modified phenol resin, an NBR rubber-modified phenol resin, a cashew-modified phenol resin, an epoxy-modified phenol resin and an alkylbenzene-modified phenol resin.
US Pat. No. 10,189,881

MPS PEPTIDES AND USE THEREOF

The Regents of the Univer...

1. A method for one or more of: reducing, delaying, inhibiting or suppressing solid tumor cell growth or metastasis; promoting apoptosis; inhibiting cancer stem cell growth; inhibiting the PIP3 level in a tumor cell; or suppressing tumor cell mobility, the method comprising contacting the cell or tissue to be treated in vivo with an effective amount of an isolated polypeptide comprising no more than 51 amino acids, wherein the amino acid sequence comprises:XXXRYSYXXSYX (SEQ ID NO: 1) and optionally, wherein one or more serines has been substituted with a neutral or positively charged amino acid, wherein each X is a lysine and wherein each Y is a phenylalanine; or
XXXXXRYSYXXSYXLSGYSYXXNXX (SEQ ID NO: 5), and optionally a polypeptide comprising any contiguous 12 amino acid fragment thereof, and/or optionally, wherein one or more serines has been substituted with a neutral or positively charged amino acid and wherein each X is a lysine and wherein each Y is a phenylalanine.
US Pat. No. 10,190,139

METHOD FOR LACTIC ACID PRODUCTION USING MONASCUS STRAINS MODIFIED FOR LACTIC ACID PRODUCTION

1. A method of producing a composition comprising lactic acid, the method comprising:(i) providing a Monascus micro-organism that is tolerant to organic acid at a concentration of at least 50 g/L and a pH of less than 5.0 and has been genetically modified for increased production of a lactic acid by the introduction of an exogenous lactate dehydrogenase (LDH) gene; and
(ii) culturing the micro-organism in a medium having a pH less than 1.5 units above the pKa value of lactic acid in the presence of hexose, pentose, or a combination thereof, as the sole carbon source.
US Pat. No. 10,189,883

THERAPEUTIC USES OF MODIFIED FGF-21 POLYPEPTIDES

BRISTOL-MYERS SQUIBB COMP...

1. A method of decreasing or inhibiting fibrosis in a patient in need thereof, comprising administering to the patient an effective amount of a modified FGF-21 polypeptide comprising a polypeptide having at least 96% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 202.
US Pat. No. 10,189,884

THIOAMIDE-MODIFIED PEPTIDES AND USES THEREOF

The Trustees of the Unive...

1. A peptide comprising the thioamide-modified amino acid sequence of SEQ ID NO:2, or a salt or solvate thereof,wherein residue 1 of SEQ ID NO:2 is the N-terminus residue of the peptide.
US Pat. No. 10,188,604

MEDICAL DEVICES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME

1. A method of treating or preventing a disease, disorder, or condition of the eye of a subject, comprising;a. providing a subject in need of treatment or prevention of said disease, disorder, or condition of the eye of said subject; and
b. providing at least one drug delivery contact lens, comprising:
i. a contact lens comprising a first surface and a second surface; and
ii. said contact lens further comprising at least one coating provided on at least a portion of said first surface, said second surface, or a combination thereof as opposed to within said contact lens;
a) said coating comprising at least one three dimensional structure;
b) said three dimensional structure comprising:
i) one or more drug reservoir layers; wherein said one or more drug reservoir layers comprise one or more drugs; and
ii) one or more barrier layers; wherein said one or more barrier layers modulafe the release of said one or more drugs from said drug delivery contact lens;
c) wherein said one or more drug reservoir layers, said one or more barrier layers, or a combination thereof, are oriented vertically, horizontally, or a combination thereof, relative to each other;
c. operably engaging said drug delivery contact lens with the eye of said subject;
wherein said one or more drugs are released from said drug delivery contact lens in an effective amount to treat or prevent a disease, disorder, or condition of the eye of said subject; and
d. wherein said subject is treated for or prevented from having or developing said disease, disorder, or condition of the eye of said subject; and
wherein said disease, disorder, or condition of the eye of said subject that is treated or prevented is an inflammation, an allergy, an infection, glaucoma, macular degeneration, a parasite, diabetes, dry eye, eye discomfort, or a combination thereof.
US Pat. No. 10,189,885

NON-HEMOLYTIC LLO FUSION PROTEINS AND METHODS OF UTILIZING SAME

The Trustees of the Unive...

1. An immunogenic composition comprising a recombinant protein comprising a listeriolysin O (LLO) protein comprising a mutation of amino acid residues on positions 2, 9 and 10 in the cholesterol-binding domain (CBD) of said LLO protein, said CBD is set forth in SEQ ID NO: 18.
US Pat. No. 10,188,605

NANOPARTICLES AND NANOPARTICLE COMPOSITIONS

Iowa State University Res...

1. An organic particle comprising a plurality of non-polymeric crosslinked amphiphiles;wherein the non-polymeric crosslinked amphiphile comprises one or more nonpolar (C6-C60)alkyl or (C6-C50)fluoroalkyl chains and one or more polar head groups;
the nonpolar chains are located on the exterior of the particle and the polar head groups are oriented toward the interior of the particle; and
the amphiphiles are covalently crosslinked to each other near the head groups through thioether groups comprising an ammonium group bonded thereto.
US Pat. No. 10,190,144

PRODUCTION OF DIRHAMNOSE-LIPID IN RECOMBINANT NONPATHOGENIC BACTERIUM PSEUDOMONAS CHLORORAPHIS

The United States of Amer...

1. A recombinant Pseudomonas chlororaphis that is derived from P. chlororaphis NRRL B-30761, said recombinant P. chlororaphis further comprises an expression vector, wherein said expression vector comprises a promoter operably linked to a heterologous polynucleotide encoding a heterologous Pseudomonas rhamnosyltransferase C, wherein rhlA and rhlB genes in said recombinant P. chlororaphis are operably linked to endogenous promoters.
US Pat. No. 10,190,402

CONTROLLING A BOTTOM-HOLE ASSEMBLY IN A WELLBORE

Halliburton Energy Servic...

1. A computer-implemented method of controlling a bottom hole assembly (BHA), the method comprising:determining, by a wellbore controller, a first candidate BHA control signal;
generating, by the wellbore controller, an input to a BHA control, the input comprising a perturbation signal superimposed on the first candidate BHA control signal;
controlling, by the wellbore controller, the BHA using the input to the BHA control;
determining, by the wellbore controller, a change in an objective value as a function of the perturbation signal, based on a received downhole sensor measurement; and
generating, by the wellbore controller and based on the change in the objective value, a second candidate BHA control signal.
US Pat. No. 10,189,890

VARIANTS OF TISSUE INHIBITOR OF METALLOPROTEINASE TYPE THREE (TIMP-3), COMPOSITIONS AND METHODS

Amgen Inc., Thousand Oak...

1. An isolated TIMP-3 mutein having a mature region that comprises the amino acid sequence of the mature region of TIMP-3 set forth in SEQ ID NO:2, wherein the mutein has(a) a mutation K45S, and
(b) a mutation F57N.
US Pat. No. 10,189,891

AFFINITY CHROMATOGRAPHY MATRIX

1. An immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal Protein A (E, D, A, B, C) or protein Z,wherein in at least one of the one or more mutated monomers the amino acid sequence of the monomer is defined by SEQ ID NO: 14, 16, 17, or 18.
US Pat. No. 10,190,148

METHOD FOR OBTAINING PEPTIDES

1. Method of obtaining peptides from procaryotic and/or eucaryotic cells, said method comprising the following steps:a) lysis of the procaryotic and/or eucaryotic cells at a low concentration of chaotropic agent(s) and recovery of the proteins thus obtained, wherein the lysis at a low concentration of chaotropic agent(s) comprises lysis by sonication performed by means of an ultrasound probe;
b) denaturation of said proteins using at least one denaturing agent,
wherein the denaturing agent is selected from the group consisting of chaotropic agents, thiol reducing agents, detergents, and combinations thereof, and
wherein the lysis and denaturation steps are performed simultaneously;
c) alkylation of the denatured proteins using at least one alkylating agent;
d) enzymatic proteolysis of the proteins obtained at the end of step c) using at least one proteolytic enzyme;
e) recovery of the peptides obtained at the end of the enzymatic proteolysis step d); and
wherein said method is performed under a pressure below 100 bars.
US Pat. No. 10,189,892

FERMENTATION PROCESS FOR ANTIBODY PRODUCTION

ALDERBIO HOLDINGS LLC, L...

1. A method for producing a recombinant protein in yeast cells, comprising the steps of:a) culturing under fed-batch fermentation conditions a population of yeast cells in a culture medium, wherein each yeast cell comprises a DNA segment encoding a polypeptide, wherein said DNA segment is operably linked to a glyceraldehyde-3-phosphate (GAP) transcription promoter and a transcription terminator, wherein the protein is not glyceraldehyde-3-phosphate, wherein the fermentation comprises a fermentable sugar feed at a first feed rate and wherein the fermentation is agitated at a first oxygen transfer rate;
b) measuring respiratory quotient (RQ) of the population during the batch fermentation and determining if it is within a desired predetermined range, wherein the desired predetermined range of RQ at about 20-40 hours after initiation of the culturing consists of a range between 1.08 and 1.35, which corresponds to a mixed metabolic condition wherein both aerobic and fermentative metabolism are taking place simultaneously;
c) adjusting one or both of the fermentable sugar feed rate to a second feed rate or the oxygen transfer rate to a second oxygen transfer rate, when the RQ is outside of a desired predetermined range;
d) repeating steps (b) and (c) one or more times throughout the step of culturing;
e) harvesting the yeast cells from the culture medium; and
f) recovering the polypeptide from the cells and/or the culture medium.
US Pat. No. 10,188,613

EXO-S-MECAMYLAMINE FORMULATION AND USE IN TREATMENT

UNIVERSITY OF SOUTH FLORI...

1. A method of treating a medical condition selected from the group consisting of substance addiction, Tourette's Syndrome, a neuropsychiatric disorder, depression, and anxiety, in a human in need thereof, comprising orally administering a therapeutically effective amount of a pharmaceutical composition to the human, wherein the pharmaceutical composition comprises:exo-S-mecamylamine or pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof,
one or more pharmaceutically acceptable carriers; and
a pharmaceutical adjuvant, wherein the pharmaceutical composition has a higher overall therapeutic index than the same amount of exo-R-mecamylamine substantially free of exo-S-mecamylamine.
US Pat. No. 10,189,895

ANTI-CGRP COMPOSITIONS AND USE THEREOF

ALDERBIO HOLDINGS LLC, L...

1. A pharmaceutical composition comprising a humanized anti-calcitonin gene related peptide (CGRP) antibody comprising a variable light (VL) chain polypeptide comprising the complementarity-determining region (CDR) polypeptides CDR1, CDR2, and CDR3, respectively, of SEQ ID NO: 55, SEQ ID NO: 56 and SEQ ID NO: 57, and a variable heavy (VH) chain polypeptide comprising the CDR polypeptides CDR1, CDR2, and CDR3, respectively, of SEQ ID NO: 58, SEQ ID NO: 59 and SEQ ID NO: 60, and a pharmaceutically acceptable excipient.
US Pat. No. 10,190,151

HIGH-THROUGHPUT AND HIGHLY MULTIPLEXED IMAGING WITH PROGRAMMABLE NUCLEIC ACID PROBES

President and Fellows of ...

1. A method comprising(1) contacting a sample being tested for the presence of one or more targets with one or more target-specific binding partners, wherein each target-specific binding partner is linked to a docking strand, and wherein target-specific binding partners of different specificity are linked to different docking strands to produce one or more targets bound to one or more target-specific binding partners,
(2) optionally removing unbound target-specific binding partners,
(3) contacting the sample with labeled imager strands that bind to docking strands,
(4) optionally removing unbound labeled imager strands,
(5) imaging the sample to detect bound labeled imager strands,
(6) inactivating the bound labeled imager strands, by removing or modifying their signal-emitting moieties without removing the imager strand in its entirety, and
(7) repeating at least some of steps (3)-(6) at least once with a labeled imager strand having a unique composition relative to at least one other labeled imager strand of step (3).
US Pat. No. 10,188,101

METHOD FOR PRODUCING AN AGRICULTURAL PRODUCT

KAO CORPORATION, Tokyo (...

1. A method for producing an agricultural product, comprising a step of applying an agricultural chemical composition comprising (A) at least one compound selected from the group consisting of the following (A1) to (A5); (B) at least one compound selected from the group consisting of the following (B1) and (B2); and an agricultural chemical ingredient selected from the group consisting of active ingredients in bactericides, pesticides, miticides, herbicides and plant growth regulators to a subject sensitive to the agricultural chemical ingredient:(A1): a polyoxyethylene alkyl ether represented by the formula (A1):
R1aO-(EO)l—R2a  (A1)
wherein, R1a represents a linear or branched, alkyl or alkenyl group having 10 to 16 carbon atoms; EO represents an ethyleneoxy group; 1 represents an average mole number of ethyleneoxy groups added, ranging from 3 to 40; and R2a represents a hydrogen atom or a methyl group,
(A2): a polyoxyethylene fatty acid ester,
wherein a fatty acid group has 8 to 16 carbon atoms; and an average number of moles of ethylene oxide added per mole of fatty acid is 5 to 40,
(A3): a polyoxyethylene sorbitan fatty acid ester,
wherein a fatty acid group has 8 to 16 carbon atoms; and an average number of moles of ethylene oxide added per mole of fatty acid is 5 to 40,
(A4): a (poly)glycerol fatty acid ester,
wherein a fatty acid group has 8 to 16 carbon atoms; and an average condensation degree of glycerol is 1 to 3, and
(A5): an alkyl saccharide represented by the formula (A5):
R3a—O-(G)p  (A5)
wherein R3a represents an alkyl group having 8 to 16 carbon atoms; G represents a reducing sugar group having 5 to 6 carbon atoms; and p represents a number of 1 to 10;
(B1): a polyoxyalkylene alkyl ether represented by the formula (B1):
R1bO—[(PO)m/(EO)n]—R2b  (B1)
wherein, R1b represents a linear or branched, alkyl or alkenyl group having 6 to 12 carbon atoms; PO represents a propyleneoxy group; EO represents an ethyleneoxy group; m represents an average mole number of propyleneoxy groups added, ranging from 2 to 20; n represents an average mole number of ethyleneoxy groups added, which is 0; and R2b represents a hydrogen atom or a methyl group; wherein “/” means that PO and EO groups may be arranged at random or in blocks, and
(B2): an aliphatic alcohol represented by the formula (B2):
R3b—OH  (B2)
wherein R3b represents a linear or branched, alkyl group having 8 to 10 carbon atoms, and wherein a weight ratio of compounds (A) to (B), (A)/(B), is 0.5 to 8.
US Pat. No. 10,188,614

PARTICULATE MATERIALS

Nektar Therapeutics, San...

1. An active substance in particulate form suitable for administration via a dry powder inhaler, said particulates comprising:a) a volume mean aerodynamic diameter of less than 7 microns;
b) a density less than 0.5 g/ml; and
c) a surface-to-volume ratio of at least twice that of spherical particles of the same volume diameter.
US Pat. No. 10,190,152

METHODS AND COMPOSITIONS FOR DIRECT CHEMICAL LYSIS

Becton, Dickinson and Com...

1. A composition consisting of a direct chemical lysis composition in combination with a liquid-based cytology sample or a formalin-fixed, paraffin embedded sample, the direct chemical lysis composition consisting of:a) a buffer composition comprising a buffer component and a metal salt component, wherein the metal salt component is selected from the group consisting of sodium chloride (NaCl), potassium chloride (KCl), sodium acetate (C2H3NaO2) and ammonium sulfate ((NH4)2SO4), wherein a concentration of the buffer component is in a range of 0.2 M to 2 M and a concentration of the metal salt component is in a range of 0.01 M to 1 M; and
b) a non-ionic surfactant wherein a concentration of the non-ionic surfactant is in a range of 0.01 to 2 percent (v/v).
US Pat. No. 10,188,615

ALKOXY COMPOUNDS FOR DISEASE TREATMENT

ACUCELA INC., Seattle, W...

1. A method of modulating chromophore flux in a retinoid cycle comprising introducing into a subject a non-retinoid aromatic compound that inhibits 11-cis-retinol production with an IC50 of about 0.1 micromolar or less when assayed in vitro, the assay consisting of a homogenate of HEK293 cell clone expressing recombinant human RPE65 and LRAT as the source of visual enzyme, exogenous all-trans-retinol in the amount of about 20 ?M, recombinant human CRALBP in the amount of about 80 ?g/mL, about 10 mM pH 7.2 phosphate buffer, about 0.5% BSA and about 1 mM NaPPi, and wherein the amount of assay reaction product 11-cis-retinol being determined by HPLC analysis following heptane extraction of the assay reaction mixture and wherein the non-retinoid aromatic compound consists of a benzene core that is substituted with a first substituent, a second substituent, and an optional third substituent, wherein the first and second substituents are attached to the benzene core in a meta-substitution configuration, wherein the first substituent is a group selected from —CH(OH)CH(R)CH2NH2 wherein R is H, CH3, or —OH and the second substituent is an optionally substituted alkoxy group, and wherein the optional third substituent is a halogen or —OH.
US Pat. No. 10,190,153

METHODS FOR PREPARATION OF NUCLEIC ACID-CONTAINING SAMPLES USING CLAY MINERALS AND ALKALINE SOLUTIONS

MICRONICS, INC., Redmond...

1. A method for treating a nucleic acid-containing sample for analysis of nucleic acids, the method comprising the steps of:a) contacting the sample with a clay mineral, wherein the clay mineral comprises a kaolinite, a smectite or a synthetic clay mineral and the sample is selected from the group consisting of blood, plasma and serum;
b) mixing the sample and the clay mineral until the clay mineral is evenly dispersed in the sample;
c) substantially removing the clay mineral from the sample;
d) contacting the sample with an alkaline solution at a pH suitable for lysis of cell and viral particles to form a nucleic acid solution; and
e) optionally, contacting the nucleic acid solution with an acidic solution suitable for neutralizing the pH of the nucleic acid solution.
US Pat. No. 10,188,616

TOPICAL SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST FORMULATIONS AND METHODS OF USING THE SAME

Teikoku Pharma USA, Inc.,...

1. A transdermal composition comprising:a sphingosine-1-phosphate receptor agonist active agent; and
a transdermal delivery vehicle comprising an adhesive matrix comprising a polyurethane, a styrenic block copolymer, a silicone and combinations thereof.
US Pat. No. 10,188,617

MODULATION OF CELLULAR DNA REPAIR ACTIVITY TO INTERCEPT MALIGNANCY

The Board of Trustees of ...

1. A method of reducing the risk of cancer in a subject having a mutation in BRCA1, comprising administering to said subject an effective amount of a DNA repair agent which is benserazide.
US Pat. No. 10,189,899

USE OF A CD6 BINDING PARTNER AND METHOD BASED THEREON

BIOCON LIMITED, Bangalor...

1. A method of treatment for multiple sclerosis in a subject, wherein the subject in need of such treatment exhibits an increased number of T helper 17 (Th17) cells when compared to a healthy subject, the method comprising:administering a humanized antibody that specifically binds to D1 of CD6 of the subject and causes a reduction of expression of IL-23R on one or more of monocytes, T helper cells and natural killer cells in a body fluid of the subject, wherein the humanized antibody is the only therapeutic antibody administered; and
monitoring IL-23R expression on blood cells and/or dendritic cells of the subject.
US Pat. No. 10,189,902

ANTIBODIES TO TIGIT

Bristol-Myers Squibb Comp...

1. An isolated antibody, or antigen binding fragment thereof, that binds to human TIGIT (human T cell immunoreceptor with Ig and ITIM domains) comprising:a) a heavy chain comprising a heavy chain variable domain comprising:
i) CDRH1 comprising the sequence of SEQ ID NO.: 20;
ii) CDRH2 comprising the sequence of SEQ ID NO.: 21; and
iii) CDRH3 comprising the sequence of SEQ ID NO.: 22;
and
b) a light chain comprising a light chain variable domain comprising:
iv) CDRL1 comprising the sequence of SEQ ID NO.: 23;
v) CDRL2 comprising the sequence of SEQ ID NO.: 24; and
vi) CDRL3 comprising the sequence of SEQ ID NO.: 25.
US Pat. No. 10,189,903

BISPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF TO TREAT CANCER

1. A bispecific chimeric antigen receptor, comprising:a. at least two antigen-specific targeting regions;
b. an extracellular spacer domain;
c. a transmembrane domain;
d. at least one co-stimulatory domain; and
e. an intracellular signaling domain,
wherein each antigen-specific targeting region comprises a single-domain antibody.
US Pat. No. 10,189,904

ANTIBODIES THAT BIND AND BLOCK TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1)

1. An isolated antibody or fragment thereof, which competes with mAb 0170 for binding to a triggering receptor expressed on myeloid cells-1 (TREM-1) having an amino acid sequence set forth as SEQ ID NO: 1 (human TREM-1), SEQ ID NO: 12 or SEQ ID NO: 21 (cynomolgus monkey TREM-1),wherein the antibody or fragment thereof comprises a heavy chain variable region that comprises CDR1, CDR2, and CDR3 domains; and a light chain variable region that comprises CDR1, CDR2, and CDR3 domains, and
wherein the heavy chain variable region CDR1 domain comprises amino acid residues 31 to 35 of SEQ ID NO: 4, the heavy chain variable region CDR2 domain comprises amino acid residues 50 to 68 of SEQ ID NO: 4, the heavy chain variable region CDR3 domain comprises amino acid residues 101 to 110 of SEQ ID NO: 4, the light chain variable region CDR1 domain comprises amino acid residues 24 to 38 of SEQ ID NO: 5, the light chain variable region CDR2 domain comprises amino acid residues 54 to 60 of SEQ ID NO: 5, and the light chain variable region CDR3 domain comprises amino acid residues 93 to 101 of SEQ ID NO: 5.
US Pat. No. 10,189,906

ANTIBODY THAT BINDS CD269 (BCMA) SUITABLE FOR USE IN THE TREATMENT OF PLASMA CELL DISEASES SUCH AS MULTIPLE MYELOMA AND AUTOIMMUNE DISEASES

1. A method for the treatment of a medical disorder in a human subject, wherein the medical disorder is associated with the presence of pathogenic B cells expressing B cell maturation antigen (BCMA), the method comprising administering to the human subject an isolated monoclonal antibody or an antigen binding fragment thereof that binds CD269 (BCMA), wherein said antibody or antigen binding fragment thereof comprises:(i) a VH domain, wherein said VH domain comprises CDR H1 comprising SEQ ID No. 1 (RYWMS) or SEQ ID No. 15 (DYWMS), CDR H2 comprising SEQ ID No. 2 (EINPDSSTINYAPSLKD) or SEQ ID No. 16 (EINPDSSTINYAPSLKG) and CDR H3 comprising SEQ ID No. 3 (SLYYDYGDAMDYW), and
(ii) a VL domain, wherein said VL domain comprises CDR L1 comprises SEQ ID No. 4 (KASQSVDSNVA), CDR L2 comprises SEQ ID No. 5 (SASLRFS) or SEQ ID No. 17 (SDDLRFS) and CDR L3 comprises SEQ ID No. 6 (QQYNNYPLTFG),
wherein the medical disorder associated with the presence of pathogenic B cells is a cancer of plasma cells or a cancer of B lymphocytes.
US Pat. No. 10,188,112

PERSONAL CLEANSING COMPOSITIONS CONTAINING ZINC AMINO ACID/TRIMETHYLGLYCINE HALIDE

Colgate-Palmolive Company...

1. A personal cleansing composition comprisinga) a skin cleansing effective amount of a surfactant, and
b) a zinc X halide complex present in an amount to provide at least 0.36 weight % of the composition of zinc,
wherein X is an amino acid or trimethylglycine;
wherein upon rinsing the skin, the composition deposits a zinc precipitate which provides an SPF factor of at least 2 to skin after washing skin with the personal cleansing composition.
US Pat. No. 10,188,628

RELEASE COMPOSITION FOR DERIVATIVES OF CANNABACEAE

1. A release composition for Cannabaceae derivatives comprising a lotion made by the process of combining:A) an aqueous phase comprising an aqueous solution or suspension containing and at least one humectant; wherein the at least one humectant is present in the aqueous phase in the range of from about 0.1 to 99 wt. %, and
B) an oil phase comprising at least one surfactant and the Cannabaceae derivatives, and optionally at least one additional oil, wherein the at least one surfactant is present in the oil phase in the range of from about 1 to 99 wt. %;
wherein the Cannabaceae derivative comprises a compound selected from the group consisting of tetrahydrocannabinol, cannabidiol, cannabichromene, cannabinol, cabbabigerol, tetrahydrocannabivarin, cannabidivarin, tetrahydrocannabinol acid, cannabidiol acid, cannabigerol acid, cannabigerovarin, cannabinovarin, and tetrahydrocannabivarin acid and combinations thereof;
wherein the aqueous phase is added to the oil phase in a weight ratio of about 3:1 to 49:1;
wherein the aqueous phase is added to oil phase using low to medium shear mixing to provide the lotion; and
wherein the lotion is hydrophobic and has release properties.
US Pat. No. 10,188,631

TOPICAL LIQUID COMPOSITION COMPRISING MELATONIN

ARES TRADING S.A., Aubon...

1. A topical liquid composition for intrauterine washing, the composition comprising:a. 2-200 ng/ml melatonin (N-acetyl-5-methoxytryptamine) or an analog thereof, or a pharmaceutically acceptable salt or solvate thereof;
b. 0.01-100 mM phosphate buffer system;
c. 1×10?6-5 mg/ml methionine or cysteine;
d. 0.0008-8 mg/ml arginine;
e. 1-100 mg/ml sodium chloride;
f. a surfactant selected from 0.001-10 mg/ml polysorbate 20 and 0.1-100 mg/ml propylene glycol; and
g. water,wherein the pH of the composition is pH 7-8.5, and the composition has an osmolality of 250-350 mOsm/kg.
US Pat. No. 10,190,173

RECURRENT GENE FUSIONS IN PROSTATE CANCER

THE REGENTS OF THE UNIVER...

1. A fluorescence in situ hybridization (FISH) method for detecting an ARG-ETS gene fusion in a sample from a subject, the method comprising:(a) hybridizing a directly labeled FISH probe to an ARG-ETS gene fusion comprising a 5? portion fused to a 3? portion, said 5? portion from an ARG gene selected from the group consisting of PSA and TMPRSS2 and said 3? portion from an ETS family member gene selected from the group consisting of ERG, ETV1 (ER81), FLI1, ETS1, ETS2, ELK1, ETV6 (TEL1), ETV7 (TEL2), GABP?, ELF1, ETV4 (E1AF; PEA3), ETV5 (ERM), ERF, PEA3/E1AF, PU.1, ESE1/ESX, SAP1 (ELK4), ETV3 (METS), EWS/FLI1, ESE1, ESE2 (ELF5), ESE3, PDEF, NET (ELK3; SAP2), NERF (ELF2), and FEV; and
(b) detecting the presence of the ARG-ETS gene fusion in the sample from the subject by detecting hybridization of the directly labeled FISH probe to a junction at which the 5? portion of the gene fusion fuses to the 3? portion of the gene fusion.
US Pat. No. 10,189,922

VERY LOW DENSITY POLYETHYLENE PRODUCED WITH SINGLE SITE CATALYST

NOVA Chemicals (Internati...

1. An ethylene copolymer havinga) a density from about 0.890 to about 0.915 g/cm3,
b) a molecular weight distribution Mw/Mn from about 2.2 to about 4.5,
c) a molecular weight distribution Mz/Mw of greater than 2, provided that when the Mz/Mw is greater than 3, the copolymer further has a normal to flat comonomer distribution,
d) a CDBI50 from about 55 to about 98, and
e) a single peak in a DSC measurement.
US Pat. No. 10,190,179

MAIZE EVENT DP-004114-3 AND METHODS FOR DETECTION THEREOF

PIONEER HI-BRED INTERNATI...

1. A method of detecting the presence of DNA corresponding to the DP-004114-3 event in a sample, the method comprising:(a) contacting the sample comprising maize DNA with a polynucleotide probe that hybridizes under stringent hybridization conditions with DNA from maize event DP-004114-3 and does not hybridize under said stringent hybridization conditions with a non-DP-004114-3 maize plant DNA;
(b) subjecting the sample and probe to stringent hybridization conditions; and
(c) detecting hybridization of the probe to the DNA;wherein detection of hybridization indicates the presence of the DP-004114-3 event.
US Pat. No. 10,188,129

METHODS FOR REDUCING OIL AND/OR FAT UPTAKE OF FRIED FOODS

DOW GLOBAL TECHNOLOGIES L...

1. An edible composition comprising starch and water-soluble cellulose ether particles, wherein at least 10 volume percent of the cellulose ether particles have a particle length LEFI of less than 40 micrometers, the cellulose ether particles have a volume fraction of fibrous particles of no more than 40%, the cellulose ether particles have a median Equivalent Projected Circle Diameter (EQPC 50,3) of up to 110 micrometers, the cellulose ether is a methylcellulose or a hydroxyalkyl methylcellulose, the viscosity of the cellulose ether is from 50 to 7,000 mPa·s when measured as a 2 wt.-% solution in water at 25° C., andwherein the composition is a dry batter mix comprising from 1 to 10 percent of the cellulose ether particles, based on the total weight of the dry batter mix.

US Pat. No. 10,194,386

TERMINAL DEVICE AND COMMUNICATION CONTROL METHOD

SHARP KABUSHIKI KAISHA, ...

1. A User Equipment (UE) comprising:reception circuitry configured for:
receiving an Inter-System Routing Policy (ISRP) and/or an Inter-APN Routing Policy (TARP), from an Access Network Discovery and Selection Function (ANDSF) located in a Home Public Land Mobile Network (PLMN);
and
receiving, from an LTE access network, Radio Access Network (RAN) information for selecting an access network; and
a controller configured for selecting the access network based on an ANDSF Policy, if the UE has both the ANDSF Policy and the RAN information,wherein:the ANDSF Policy includes the ISRP and/or the IARP, and
the access network is selected from between the LTE access network and a WLAN access network.

US Pat. No. 10,194,384

WIRELESS COMMUNICATION SYSTEM, BASE STATION, AND TERMINAL

FUJITSU LIMITED, Kawasak...

1. A wireless communication system comprising:a terminal configured to perform wireless communication concurrently using a cell of a first type enabling connection without association with another cell and a cell of a second type enabling connection by being associated with the cell of the first type; and
a base station configured to form a first cell of the second type and when detecting that the terminal selects the first cell for the cell of the first type, the base station notifies the terminal of a second cell of the first type different from the first cell so as to allow the terminal to change connection to the second cell.

US Pat. No. 10,194,377

NETWORK DEVICE AND DATA BACKHAUL IMPLEMENTATION SYSTEM AND METHOD

HUAWEI TECHNOLOGIES CO., ...

1. A network device, comprising a memory, and a processor, wherein the memory stores a group of program code, and the processor is configured to call the program code stored in the memory, to execute the following operations:obtaining, according to channel state information, a backhaul request of a second network device, residual backhaul capability information of a third network device, and backhaul control information used for controlling the second network device and the third network device to backhaul data, wherein the backhaul control information comprises backhaul network topology control information and physical resource allocation information;
broadcasting the backhaul control information to the second network device and the third network device, so that the second network device and the third network device backhaul data according to the backhaul control information; and
broadcasting a reference signal instruction message to the second network device and the third network device, wherein the reference signal instruction message is used to instruct one or more network devices of the second network device or the third network device to send a reference signal and another network device to measure the channel state information.

US Pat. No. 10,194,373

SELF-EVOLVING WIRELESS BACKHAUL

KABUSHIKI KAISHA TOSHIBA,...

13. A method of operating a wireless network comprising a plurality of wireless devices and a backbone, the method comprising:one of the wireless devices initiating data upload to the backbone or a data download from the backbone;
the initiating wireless device estimating, based on rules defining benefits to be received by initiating wireless devices and costs incurred by the initiating wireless devices within the network when the wireless devices participate in data transfer in a network and on information of topology of the network formed by the wireless devices, costs of uploading or downloading the data via other wireless devices in the network;
the initiating wireless device estimating the costs of uploading or downloading the data directly to/from the backbone;
wherein one or both estimates combine an estimation of technical costs of data transmission, their compensation payments and path length dependent network benefits;
determine whether at least one of costs or benefits of a direct data exchange with the backbone outweigh those of data exchange with the backbone via other nodes; and
the initiating wireless device initiating the upload or requesting the download directly from the backbone or via the other wireless devices based on the determination; and
further comprising a cache storage, the method further comprising:
checking whether or not predetermined data is stored in the cache upon receipt of a request from another wireless device for transmission of the predetermined data;
performing a cost/benefit analysis of transmitting the predetermined data to the other wireless device; and
if the cost/benefit analysis indicates that transmission of the predetermined data is advantageous for the wireless device, reading the predetermined data from the cache and transmitting the read data to the other wireless device.

US Pat. No. 10,194,371

COMMUNICATION APPARATUS AND CONTROL METHOD OF COMMUNICATION APPARATUS

CANON KABUSHIKI KAISHA, ...

1. A communication apparatus comprising:one or more processors; and
one or more memories including instructions that, when executed by the one or more processors, cause the apparatus to:
obtain, by a communication that conforms to a first communication scheme, execution information representing whether or not a first apparatus is executing a relay function that enables the communication apparatus to communicate with a second apparatus via the first apparatus;
request, by the communication that conforms to the first communication scheme, the first apparatus to start the relay function, in a case where the execution information represents that the first apparatus is not executing the relay function;
communicate with the second apparatus via the first apparatus, by performing a communication that conforms to a second communication scheme that is different from the first communication scheme with the first apparatus that is executing the relay function;
determine whether the first apparatus has been requested to start the relay function in a case where the communication with the second apparatus is terminated; and
request the first apparatus to stop the relay function in a case where it is determined that the first apparatus has been requested to start the relay function, and not request the first apparatus to stop the relay function in a case where it is determined that the first apparatus has not been requested to start the relay function.

US Pat. No. 10,194,370

PROXIMITY INFORMATION IN CONFIGURATION OF DATA LINKS IN WIRELESS NETWORKS

INTEL IP Corporation, Sa...

23. A device, comprising:an access unit that identifies proximity information representative of an amount of physical separation of the device from a second device;
a configuration unit that configures a data link with the second device; and
an assignment unit that associates the data link to a data path group associated with a cluster of devices including the device, wherein the data link is associated based on a portion of the proximity information and at least one of second proximity information associated with extant data links or third proximity information associated with data path groups, wherein the proximity information is based on a received signal strength indication (RSSI), the second proximity information is based on a second RSSI, and the third proximity information is based on a third RSSI.

US Pat. No. 10,194,359

METHOD AND SYSTEM FOR STATION LOCATION BASED NEIGHBOR DETERMINATION AND HANDOVER PROBABILITY ESTIMATION

InterDigital Technology C...

1. A method for an access controller (AC), comprising:receiving, by the AC, reports from a plurality of wireless devices, wherein each report includes geographic location information of each wireless device;
maintaining network topology information, by the AC, based on the reports from the plurality of wireless devices; and
providing network topology information to at least one wireless device in response to receiving a request for information.

US Pat. No. 10,194,354

AVAILABILITY BASED NETWORK SELECTION

Sprint Spectrum L.P., Ov...

1. A method of operating a communication system, comprising:determining, by a control element of a target wireless communication network, that a wireless device is being served by a source wireless communication network;
determining, by the target wireless communication network, that a base station of the target wireless communication network is available to serve the wireless device;
deciding, by the control element of the target wireless communication network, that the wireless device should be handed over from the source wireless communication network to the target wireless communication network based on the determination that the target wireless communication network is available to serve the wireless device; and
instructing, by the control element of the target wireless communication network, the source wireless communication network to handover the wireless device to the target wireless communication network based on the decision that the target wireless communication network is available to serve the wireless device.

US Pat. No. 10,194,350

BASE STATION, WIRELESS COMMUNICATION SYSTEM, AND COMMUNICATION METHOD

NEC Corporation, Tokyo (...

1. A base station, comprising:a controller configured to control a downlink data flow, to a terminal, via another base station based on feedback from the another base station;
a transmitter configured to transmit, to the another base station, downlink data and a parameter containing a value of 0 or 1; and
a receiver configured to receive the feedback from the another base station if the parameter contains the value of 1, wherein:
the value of 0 indicates that the feedback is not requested, and the value of 1 indicates that the feedback is requested, and
the base station is configured for a split bearer option.

US Pat. No. 10,194,339

DETECTION OF BASE STATION SYNCHRONIZATION FAILURE

Sprint Communications Com...

10. One or more non-transitory computer-readable media having computer-executable instructions embodied thereon that, when executed, perform a method for detecting synchronization failures between base stations in a wireless communications network, the method comprising:at each of a plurality of base stations:
generating a cancellation signal that is in-phase relative to signals output over a downlink band by a first base station and that has an inverse amplitude relative to the signals output over the downlink band by the first base station;
internally cancelling receipt, in near real time at the first base station, of the signals output over the downlink band by the first base station using the cancellation signal;
listening for synchronization information output by a neighboring base station over the downlink band as enabled by the signal receipt cancellation;
when synchronization information output over the downlink band by the neighboring base station is received at the first base station, communicating the synchronization information of the neighboring base station and synchronization information of the first base station to a server for detection of synchronization failures.

US Pat. No. 10,194,309

ROAMING SUPPORT FOR WIRELESS ACCESS SUBSCRIBER OVER FIXED IP ACCESS NETWORKS

1. A method, comprising:evaluating, by a system comprising a processor, a first service level agreement, which is a default service level agreement corresponding to first network devices of a first network, comprising a wired connection between a wired device of the first network devices and an 802.1x based wireless access point device of the first network devices, and second network devices of a second network that facilitates cellular based communications of a wireless device, wherein the first network facilitates a transfer, via the wired connection between the wired device and the 802.1x based wireless access point device, of an internet protocol communication between the wired device and the 802.1x based wireless access point device; and
in response to determining a deficiency of the first service level agreement with respect to providing, via the wired connection between the wired device and the 802.1x based wireless access point device, the internet protocol based communication to the wireless device,
initiating, by the system based on a defined rule, a negotiation of a second service level agreement establishing, for a class of subscribers associated with respective wireless devices comprising the wireless device based on quality of service parameters comprising a priority of a router device of the first network devices, policies of data exchange between the first network devices of the first network and the second network devices of the second network, wherein a policy of the policies specifies a payment, based on a billing classification corresponding to the priority of the router device, to be sent from a cellular network provider identity of the second network to a network provider identity of the first network for provision, via the wired connection between the wired device and the 802.1x based wireless access point device utilizing the router device of the first network devices, of the internet protocol based communication to the wireless device, and
in response to billing the network provider identity of the first network based on the second service level agreement, sending, by the system via the wired connection between the wired device and the 802.1x based wireless access point device, the internet protocol based communication to the wireless device.

US Pat. No. 10,194,308

WIRELESS NETWORK ROAMING IN HIGH-SPEED MOVEMENT APPLICATIONS

Cisco Technology, Inc., ...

1. An apparatus comprising:a first wireless bridge device configured to transmit signals to and receive signals from wireless network access points located along a pathway; and
a second wireless bridge device configured to transmit signals to and receive signals from the wireless network access points,
the first wireless bridge device and the second wireless bridge device being coupled to and in communication with each other so that when the first wireless bridge device is wirelessly connected to a first access point and about to initiate a roaming mode to attempt to wirelessly connect to a second access point, the first wireless bridge device notifies the second wireless bridge device of the initiating of the roaming mode and determines whether the second wireless bridge device is in the roaming mode while the apparatus is moving along the pathway.

US Pat. No. 10,194,304

METHODS FOR RECEIVING DEVICE DISCOVERY INFORMATION AND SENDING DEVICE DISCOVERY INFORMATION AND USER EQUIPMENT

1. A method for receiving device discovery information, comprising:receiving, by first User Equipment (UE), device discovery information sent by second UE, wherein the device discovery information contains at least one piece of the following information: UE identification information and attribute information of the UE; and
performing, by the first UE, Device-to-Device (D2D) discovery and/or D2D communication under the condition that the device discovery information is consistent with a preset condition;
wherein the attribute information of the UE comprises at least one piece of the following information: an attribute update count value, UE capability information, UE type information, UE group information, UE state information, UE coverage information and application related information;
wherein performing, by the first UE, D2D discovery and/or D2D communication under the condition that the device discovery information is consistent with the preset condition comprises:
under the condition that the device discovery information contains an attribute update count value, judging, by the first UE, whether the information of the second UE and the corresponding attribute update count value have been received or not, and based on that the information of the second UE and the corresponding attribute update count value have not been received and/or the received attribute update count value is different, storing, by the first UE, the attribute update count value in the device discovery information, and acquiring other attribute information; and/or
under the condition that the device discovery information contains relay capability information of the second UE, storing, by the first UE, the second UE, and when the first UE searches for a relay node for signalling and data forwarding, employing the second UE as a candidate relay node; and/or
under the condition that the device discovery information contains indication information about whether the second UE has D2D communication capability or not, judging, by the first UE, whether to initiate D2D communication with the second UE or not according to the indication information about whether the second UE has the D2D communication capability information or not; and/or
under the condition that the device discovery information contains D2D capability profile information of the second UE, selecting, by the first UE, a plurality of communication parameters when initiating establishment of a D2D communication connection with the second UE according to the D2D capability profile information of the second UE; and/or
under the condition that the device discovery information contains type information of the second UE, responding to, by the first UE, UE with a high priority and/or UE of an emergency help calling user according to the type information of the second UE; and/or
under the condition that the device discovery information contains group information of the second UE and the first UE also belongs to a group indicated by the group information, performing, by the first UE, D2D group-based device discovery according to the group information of the second UE; and/or
under the condition that the device discovery information contains state information of the second UE, performing, by the first UE, D2D discovery and D2D communication flows according to a state of the second UE; and/or
under the condition that the device discovery information contains coverage information of the second UE, finishing, by the first UE, device discovery and/or D2D communication connection establishment with the second UE through a serving eNB of the first UE according to the coverage information of the second UE; and/or
under the condition that the device discovery information contains application related information of the second UE, judging, by the first UE, whether an application indicated by the application related information of the second UE is an application in which the first UE is interested or not, and if YES, presenting, by the first UE, preset information corresponding to the application in which the first UE is interested.

US Pat. No. 10,194,297

INFORMATION PROCESSING APPARATUS, INFORMATION PROCESSING METHOD, AND NON-TRANSITORY COMPUTER READABLE MEDIUM

FUJI XEROX CO., LTD., Mi...

1. An information processing apparatus comprising:at least one hardware processor configured to implement:
a session generating unit that generates, in a case where an operation is accepted from a first terminal with a user not uniquely identified, first session information in association with the first terminal, the first session information serving as a unit for managing communication for the first terminal, and that generates, in a case where an operation is accepted from a second terminal, second session information in association with the second terminal, the second session information serving as a unit for managing communication for the second terminal;
an associating unit that associates the first session information with the second session information by updating at least one of the first session information and the second session information to identify another of the first session information and the second session information in a case where an operation for associating the first terminal with the second terminal is accepted; and
a processing unit that performs, in a case where the first session information is associated with the second session information, a process using an operation log that is stored in association with the first terminal, in response to an operation performed using the second terminal.

US Pat. No. 10,194,283

METHOD FOR CONTROLLING A PORTABLE RADIO COMMUNICATION DEVICE TO PARTICIPATE IN A TALK GROUP CALL

MOTOROLA SOLUTIONS, INC.,...

1. A method of controlling a portable radio communication device to participate in a talk group call, the method comprising:receiving, at the portable radio communication device, a signal including a first hash value transmitted by at least one other portable radio communication device;
selecting a wireless access point that is within a communication range of the portable radio communication device;
applying a hash function to a device identifier that is uniquely associated with the wireless access point to generate a second hash value;
comparing the first hash value with the second hash value; and
controlling the portable radio communication device to participate in a talk group call with the at least one other portable radio communication device when the first hash value matches with the second hash value.

US Pat. No. 10,194,279

METHODS, SYSTEMS, AND PRODUCTS FOR ENHANCED LOCATION

1. A portable product for use in conjunction with an electrical outlet, the portable product comprising:a transceiver associated with an electrical outlet;
a memory device that stores an algorithm; and
a processor that executes the algorithm to perform operations, the operations comprising:
receiving, via the transceiver, a near field wireless signal transmitted from a mobile device, the near field wireless signal comprising a device identifier associated with the mobile device;
generating, by the processor, an outlet message that includes the device identifier and an outlet identifier associated with the electrical outlet, the outlet identifier identifying the electrical outlet as an indoor location of the mobile device; and
transmitting, by the processor, the outlet message via a wireless local area network to a network device, the outlet message enabling an electronic logging of the outlet identifier as the indoor location of the mobile device.

US Pat. No. 10,194,272

PEER DISCOVERY IN TRANSACTIONAL MOBILE APPLICATIONS

QUALCOMM Incorporated, S...

1. A method of peer discovery, comprising:receiving from a server, at a first device, a meeting location and information for communication with a second device;
obtaining a series of location data related to the second device, wherein the location data is based on a non-device-to-device positioning;
determining whether to perform a direct device-to-device positioning with the second device using the meeting location and information for communication with the second device;
performing a series of last-stretch direct device-to-device positioning measurements between the first device and the second device in response to a determination to perform the direct device-to-device positioning with the second device; and
identifying the second device based on a series of last-stretch direct device-to-device ranges approaching zero, wherein the series of last-stretch direct device-to-device ranges is based on the series of last-stretch device-to-device positioning measurements between the first device and the second device.

US Pat. No. 10,194,256

METHODS AND APPARATUS FOR ANALYZING MICROPHONE PLACEMENT FOR WATERMARK AND SIGNATURE RECOVERY

The Nielsen Company (US),...

1. An apparatus to analyze microphone placement for watermark extraction and signature generation, the apparatus comprising:a signal transformer to determine a frequency spectrum of a noise burst received with a microphone, the noise burst converted to a digital signal with a meter communicatively coupled to the microphone and the signal transformer;
a variance determiner to compute a variance of a magnitude spectrum of at least one of a first frequency band associated with first media or a second frequency band associated with second media, the first and second frequency bands corresponding to the digital signal representative of the frequency spectrum; and
a detection rates determiner to:
determine, based on the computed variance and at least one of a first mapping for the first frequency band or a second mapping for the second frequency band, a recovery rate associated with at least one of watermark detection or signature generation performed on an audio signal of at least one of the first or second frequency band corresponding to the first and second media, respectively, received with the microphone, the recovery rate corresponding to a placement of the microphone; and
output the recovery rate to a user interface.